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Abstract
Background: The link between the abnormalities of the Hypothalamic-pituitary-adrenal (HPA) axis and depression has
been one of the most consistently reported findings in Psychiatry. At the same time, multiple studies have
demonstrated a stronger association between the increased activation of HPA-axis and melancholic, or endogenous
depression subtype. This association has not been confirmed for the atypical subtype, and some researchers have
suggested that as an antinomic depressive subtype, it may be associated with the opposite type, i.e. hypo-function, of
the HPA-axis, similarly to PTSD. The purpose of this systematic review is to summarise existing studies addressing
the abnormalities of the HPA-axis in melancholic and/or atypical depression. Methods: We conducted a systematic
review of the literature by searching MEDLINE, PsycINFO, OvidSP and Embase databases until June 2017. The
following search items were used: "hypothalamic-pituitary-adrenal" OR "HPA" OR "cortisol" OR "corticotropin releasing
hormone" OR "corticotropin releasing factor" OR "glucocorticoid*" OR "adrenocorticotropic hormone" OR "ACTH" AND
"atypical depression" OR "non-atypical depression" OR "melancholic depression" OR "non-melancholic depression"
OR "endogenous depression" OR "endogenomorphic depression" OR "non-endogenous depression". Search limits
were set to include papers in English or German language published in peer-reviewed journals at any period. All
studies were scrutinized to determine the main methodological characteristics, and particularly possible sources of
bias influencing the results reported. Results: We selected 48 relevant studies. Detailed analysis of the methodologies
used in the studies revealed significant variability especially regarding the samples’ definition comparing the HPA axis
activity of melancholic patients to atypical depression, including healthy controls. The results were subdivided into 4
sections: 1) 27 studies which compared melancholic OR endogenous depression vs. non-melancholic or non-
endogenous depression or controls; 2) 9 studies which compared atypical depression or atypical traits vs. non-atypical
depression or controls; 3) 7 studies which examined melancholic or endogenous and atypical depression subtypes
and 4) 5 studies which used a longitudinal design, comparing the measures of HPA-axis across two or more time
points. While the majority of studies did confirm the association between melancholic depression and increased post-
challenge cortisol levels, the association with increases in basal cortisol and basal ACTH were less consistent. Some
studies, particularly those focusing on reversed vegetative symptoms, demonstrated a decrease in the activity of the
HPA axis in atypical depression compared to controls, but the majority did not distinguish it from healthy controls.
Conclusion: In conclusion, our findings indicate that there is a difference in the activity of the HPA-axis between
melancholic and atypical depressive subtypes. However, these are more likely explained by hypercortisolism in
melancholia; and most often normal than decreased function in atypical depression. Further research should seek to
distinguish a particular subtype of depression linked to HPA-axis abnormalities, based on symptom profile, with a
focus on vegetative symptoms, neuroendocrine probes, and the history of adverse childhood events. New insights into
the dichotomy addressed in this review might be obtained from genetic and epigenetic studies of HPA-axis related
genes in both subtypes, with an emphasis on the presence of vegetative symptoms.
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HIGHLIGHTS
1. Different depressive subtype classification criteria may influence severity and
treatment.
2. Depressive subtype is an important factor influencing Hypothalamus-Pituitary-Adrenal
(HPA) axis activity
3. Melancholic patients has increased post-challenge cortisol levels than Atypical
Depressive patients
4. Studies focusing on reversed vegetative symptoms, demonstrated a decrease in the
activity of the HPA axis in atypical depressives compared to controls, but the majority
did not distinguish it from healthy controls.
5. The correct definition of depression subtypes remains a cornerstone in biological
research in affective disorders.
6. Future studies should consider epigenetic studies of HPA-axis related to both subtypes,
with an emphasis on vegetative symptom and standardized methodologies.
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 Abstract
Background: The link between the abnormalities of the Hypothalamic-pituitary-adrenal (HPA) axis 
and depression has been one of the most consistently reported findings in psychiatry. At the same 
time, multiple studies have demonstrated a stronger association between the increased activation 
of HPA-axis and melancholic, or endogenous depression subtype.  This association has not been 
confirmed for the atypical subtype, and some researchers have suggested that as an antinomic 
depressive subtype, it may be associated with the opposite type, i.e. hypo-function, of the HPA-
axis, similarly to PTSD.  The purpose of this systematic review is to summarise existing studies 
addressing the abnormalities of the HPA-axis in melancholic and/or atypical depression.
Method: We conducted a systematic review in the literature by searching MEDLINE, PsycINFO, 
OvidSP and Embase databases until June 2017. The following search items were used: 
"hypothalamic-pituitary-adrenal" OR "HPA" OR "cortisol" OR "corticotropin releasing hormone" OR 
"corticotropin releasing factor" OR "glucocorticoid*" OR "adrenocorticotropic hormone" OR "ACTH" 
AND "atypical depression" OR "non-atypical depression" OR "melancholic depression" OR "non-
melancholic depression" OR "endogenous depression" OR "endogenomorphic depression" OR 
"non-endogenous depression". Search limits were set to include papers in English or German 
language published in peer-reviewed journals at any period. All studies were scrutinized to 
determine the main methodological characteristics, and particularly possible sources of bias 
influencing the results reported.
Results: We selected 48 relevant studies. Detailed analysis of the methodologies used in the 
studies revealed significant variability especially regarding the samples’ definition comparing the 
HPA axis activity of melancholic patients to atypical depression, including healthy controls. The 
results were subdivided into 4 sections: 1) 27 studies which compared melancholic OR 
endogenous depression vs. non-melancholic or non-endogenous depression or controls; 2) 9 
studies which compared atypical depression or atypical traits vs. non-atypical depression or 
controls; 3) 7 studies which compared melancholic or endogenous and atypical depression 
subtypes and 4) 5 studies which used a longitudinal design, comparing the measures of HPA-axis 
across two or more time points. While the majority of studies did confirm the association between 
melancholic depression and increased post-challenge cortisol levels, the association with 
increases in basal cortisol and basal ACTH were less consistent. Some studies, particularly those 
focusing on reversed vegetative symptoms, demonstrated a decrease in the activity of the HPA 
axis in atypical depression compared to controls, but the majority did not distinguish it from healthy 
controls.
Conclusions: In conclusion, our findings indicate that there is a difference in the activity of the 
HPA-axis between melancholic and atypical depressive subtypes. However, these are more likely 
explained by hypercortisolism in melancholia; and most often normal than decreased function in 
atypical depression. Further research should seek to distinguish a particular subtype of depression 
linked to HPA-axis abnormalities, based on symptom profile, with a focus on vegetative symptoms, 
neuroendocrine probes, and the history of adverse childhood events. New insights into the 
dichotomy addressed in this review might be obtained from genetic and epigenetic studies of HPA-
axis related genes in both subtypes, with an emphasis on the presence of vegetative symptoms.  
Keywords: hypothalamic-pituitary-adrenal axis; cortisol, ACTH; atypical depression; melancholic 
depression; endogenous depression.
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Abstract
The link between the abnormalities of the Hypothalamic-pituitary-adrenal (HPA) axis and 
depression has been one of the most consistently reported findings in psychiatry. At the 
same time, multiple studies have demonstrated a stronger association between the 
increased activation of HPA-axis and melancholic, or endogenous depression subtype.  This 
association has not been confirmed for the atypical subtype, and some researchers have 
suggested that as an antinomic depressive subtype, it may be associated with the opposite 
type, i.e. hypo-function, of the HPA-axis, similarly to PTSD. The purpose of this systematic 
review is to summarise existing studies addressing the abnormalities of the HPA-axis in 
melancholic and/or atypical depression. We conducted a systematic review in the literature 
by searching MEDLINE, PsycINFO, OvidSP and Embase databases until June 2017. The 
following search items were used: "hypothalamic-pituitary-adrenal" OR "HPA" OR "cortisol" 
OR "corticotropin releasing hormone" OR "corticotropin releasing factor" OR 
"glucocorticoid*" OR "adrenocorticotropic hormone" OR "ACTH" AND "atypical depression" 
OR "non-atypical depression" OR "melancholic depression" OR "non-melancholic 
depression" OR "endogenous depression" OR "endogenomorphic depression" OR "non-
endogenous depression". Search limits were set to include papers in English or German 
language published in peer-reviewed journals at any period. All studies were scrutinized to 
determine the main methodological characteristics, and particularly possible sources of bias 
influencing the results reported. We selected 48 relevant studies. Detailed analysis of the 
methodologies used in the studies revealed significant variability especially regarding the 
samples’ definition comparing the HPA axis activity of melancholic patients to atypical 
depression, including healthy controls. The results were subdivided into 4 sections: 1) 27 
studies which compared melancholic OR endogenous depression vs. non-melancholic or 
non-endogenous depression or controls; 2) 9 studies which compared atypical depression or 
atypical traits vs. non-atypical depression or controls; 3) 7 studies which compared 
melancholic or endogenous and atypical depression subtypes and 4) 5 studies which used a 
longitudinal design, comparing the measures of HPA-axis across two or more time points. 
While the majority of studies did confirm the association between melancholic depression 
and increased post-challenge cortisol levels, the association with increases in basal cortisol 
and basal ACTH were less consistent. Some studies, particularly those focusing on reversed 
vegetative symptoms, demonstrated a decrease in the activity of the HPA axis in atypical 
depression compared to controls, but the majority did not distinguish it from healthy controls. 
In conclusion, our findings indicate that there is a difference in the activity of the HPA-axis 
between melancholic and atypical depressive subtypes. However, these are more likely 
explained by hypercortisolism in melancholia; and most often normal than decreased 
function in atypical depression. Further research should seek to distinguish a particular 
subtype of depression linked to HPA-axis abnormalities, based on symptom profile, with a 
focus on vegetative symptoms, neuroendocrine probes, and the history of adverse childhood 
events. New insights into the dichotomy addressed in this review might be obtained from 
genetic and epigenetic studies of HPA-axis related genes in both subtypes, with an 
emphasis on the presence of vegetative symptoms.  
Keywords: hypothalamic-pituitary-adrenal axis, cortisol, atypical depression, 
melancholic depression, endogenous depression.
Introduction
Major depression is undoubtedly one of the major healthcare issues in the 
21st century According to the latest WHO report on 23 February 2017, depression is 
now ranked as the single largest contributor of years lived with disability worldwide, 
and the major contributor to the global burden of disease. (WHO, 2017)
Stress response system abnormalities in Depression
The most robust and consistent finding in major depression so far has been its link to 
the abnormalities of the stress response system. The stress response system is a 
complex, multilevel mechanism largely dependent on feedback regulation. It relies 
on two main elements - the autonomic stress response which exerts immediate 
effects when the organism is faced with physiological or psychological stressors; and 
the impact on the hypothalamo-pituitary-adrenal (HPA) axis.  A detailed account of 
the structure and physiology of both components of the stress response system is 
thoroughly given by Ulrich-Lai & Herman (2009) and is outside the scope of this 
review. However, to understand the nature of the abnormalities which will be 
discussed further, it is essential to highlight the key characteristics of the HPA-axis.
In response to stressful stimuli, the suppression of the subgenual prefrontal cortex 
and the activation of amygdala lead to the stimulation of the autonomic sympathetic 
axis, and the HPA axis (Dioro et al. 1993; Phelps and LeDoux, 2015; Gold, 2015). 
The autonomic sympathetic axis is responsible for the most rapid response, and acts 
via the secretion  of epinephrine by the adrenal glands; the HPA axis is activated 
minutes after the epinephrine surge, and represents a cascade of events starting 
with the secretion of the corticotropin releasing factor (CRF, also known as 
corticotropin-releasing hormone, or CRH) from the paraventricular nucleus of the 
hypothalamus into the portal circulation, which stimulates the synthesis and release 
of adrenocorticotropic hormone (ACTH) by the pituitary.  The ACTH further 
stimulates the synthesis and release of the glucocorticoid hormone cortisol by the 
adrenal cortex. Glucocorticoids are known to exert a range of functions, such as 
promoting gluconeogenesis, catabolic and antianabolic activity, suppression of 
innate immunity in immune organs, insulin resistance and a prothrombotic state. The 
key role of glucocorticoids consists in maintaining homoeostasis in response to 
stress (Juruena, 2014). 
    The HPA-axis exerts its feedback through two major types of receptors: the 
glucocorticoid (GR) and the mineralocorticoid (MR) receptors. MRs have higher 
affinity to cortisol which results in their higher occupancy even at basal cortisol 
concentrations; at the same time, they are less specific and bind with both cortisol 
and aldosterone. GRs, on the other hand, bind more specifically to cortisol, yet 
respond to higher concentrations than MRs  MR’s seem to be the ones that regulate 
cortisol feedback du-ring acute or normal stress. However, during severe or 
prolonged stress, GR’s come into action (De Kloet et al.,1998). 
    The abnormalities of stress response system in affective disorders have been 
implied in several hundred studies (Stetler et al. 2013).  However, accumulating 
evidence suggests that the presence, and type of, HPA-axis abnormalities may vary 
across various subtypes of depression (Gold et al. 2015; Porter and Gallagher 
2006). Some studies have shown a robust association with HPA-axis overactivity 
with more severe or endogenomorphic forms of depression such as melancholic 
depression or psychotic depression (Nelson and Davis 1997).At the same time, in 
posttraumatic stress disorder, an enhanced HPA negative feedback was described 
(Yehuda et al. 1991). Some studies have hypothesised that atypical depression, 
unlike the melancholic subtype and similar to PTSD, is characterised by 
hypocortisolism and enhanced negative feedback. However, whether it is fair to 
claim there exists such a dichotomy, is not clear at the moment. 
    The aim of the current article is to review existing literature addressing the function 
of the HPA-axis in melancholic and atypical depressive subtypes.  Evaluate whether: 
a) there is a significant difference between the two subtypes in terms of the activity of 
the HPA-axis; b) whether there is enough evidence to suggest that the HPA-axis is 
overactive in depression with melancholic features; c) whether there is sufficient 
evidence to indicate that the HPA-axis in depression with atypical features is 
hypoactive.
Melancholic vs atypical depression: a historical perspective on subtype 
definition and boundaries. 
Considering the studies which have addressed HPA-axis abnormalities in either of, 
or both, melancholic and atypical subtypes, it is important to take into account that 
over the recent decades, approaches to identify them have been changing, and even 
today, appropriate criteria defining both subtypes remain a matter of debate.
A specifier introduced in DSM-III (1980),  depression with melancholic features 
represents a subtype of depression clinically characterized by a distinct pattern of 
low mood, anhedonia, lack of reactivity to positive events, loss of appetite and 
weight, insomnia, loss of libido and diurnal mood variations.  Although depression 
with «me-lancholic features» has been validated extensively (Shotte et al, 1997; 
Juruena et al 2011; Parker et al, 2015), there is still little agreement among 
researchers regarding the particular set of features that define it (Maes et al., 1992; 
Leventhal et al, 2005 ; Fink et al, 2007; Parker et al, 2013). Besides, the various 
diagnostic measures used for identifying melancholic depression have shown a 
considerable degree of inconsistency, as exemplified by the comparison of Research 
Diagnostic Criteria (RDC) endogenous depression definition, Newcastle scale 
endogenous depression definition, and DSM-III and DSM-IV diagnoses of 
melancholic depression (Rush et al., 1994 ; Coryell, 2007 Orsel et al., 2010). 
    Nevertheless, it is of high importance for this review to point out that the sub-
sample identified by researchers as non-melancholic can be highly heterogeneous 
and represent various diagnostic entities, such as neurotic/reactive, atypical, non-
differentiated depression, characterological depression (Fink and Taylor, 2007). 
Therefore, although atypical depression is indeed greatly antithetic to melancholic 
depression, it is not the same as non-melancholic depression, and for the purpose of 
this review, unless specified as having features known to constitute the atypical 
subtype, non-melancholic subsamples of reviewed studies will not be not considered 
atypical.
    Atypical depression had been recognized by some researchers as a depressive 
subtype since the 1960s. However, although addressed extensively in the context of 
differential responsiveness to pharmacological treatment, it had not been included in 
official DSM diagnostic criteria until 1994, following the formulation of Columbia 
atypical depression criteria (Quitkin et al. 1993).  The validity of the atypical specifier 
has been demonstrated by some studies, that largely rests on data from 
psychopharmacological research - an approach introduced by Klein and according to 
which, the differential response to biological treatment represents different 
pathophysiology (Klein, 1989) and genetic-epidemiological studies which indicated 
that atypical depression subtype is genetically distinct from typical ones, which 
represents its etiological insularity (Kendler et al., 1996; Sullivan et al..1998). At the 
same time, the precise definition of «atypical depression» remains a matter of 
debate. According to DSM-IV diagnostic criteria (“atypical features” specifier), the 
disorder is primarily characterized by mood reactivity and 2 or more of the following 
symptoms as predominant features in patients with major depression or dysthymic 
disorder: overeating, oversleeping, “leaden paralysis,” and interpersonal rejection 
sensitivity. The relevance of mood reactivity to the subtype, as well as its relationship 
with other symptoms, has been questioned. The studies cited above as providing 
evidence for the validity of the subtype, in fact, did not include the «mood reactivity» 
criteria. In a study by Posternak et al. (2001) mood reactivity did not show any 
association with any other psychopathological features of the proposed subtype. 
Similar results were reported by a few other researchers (Parker et al., 2002).  A 
much more robust association was shown for the component of the symptom 
definition described as «re-versed vegetative symptoms», namely hyperphagia and 
hypersomnia, and some of the studies selected for this review have focused on 
these characteristics rather than the DSM-defined specifier (Benazzi, 2002). In two 
studies of treatment response, Stewart et al. (2007) demonstrated a significant 
contribution of  factors such as age of onset (early vs late) and chronicity (chronic or 
remitting course) to the correlation between atypical subtype and response to MAOI 
treatment.. Some authors proposed a reappraisal of the DSM criteria for an atypical 
subtype to reduce the number of symptoms besides mood reactivity to one, and to 
include the onset of dysphoria before 20 and chronic course as additional criteria. 
However, DSM-5 saw no amendments to the subtype criteria (Stewart et al. 2007).
Therefore, the definition of the atypical subtype appears even more vague than that 
of melancholic subtype, and data of all biological studies should be interpreted with 
account of the characteristics of the phenotype. Besides, in the majority of studies, 
as well as in the case with non-melancholic depression, the non-atypical descriptor 
does not necessarily identify melancholic depression, therefore, unless specified 
otherwise, non-atypical depression is considered as MDD not matching particular 
subtype criteria.
Methods
We conducted a systematic review of the literature by searching Ovid MEDLINE(R) 
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily and Ovid MEDLINE(R) 1946 to Present, PsycINFO, Journals@Ovid Full Text 
and Embase databases using the Ovid platform.
The following search items were used: 
"hypothalamic-pituitary-adrenal" OR "HPA" OR "cortisol" OR "corticotropin releasing 
hormone" OR "corticotropin releasing factor" OR "glucocorticoid*" OR 
"adrenocorticotropic hormone" OR "ACTH" AND "atypical depression" OR "non-
atypical depression" OR "melancholic depression" OR "non-melancholic depression" 
OR "endogenous depression" OR "non-endogenous depressive» Search limits were 
set to include papers in English or German language, published in peer-reviewed 
journals at any period. Fig. (1) shows details of the search strategy.
The initial search yielded 9556 results in total, which was comprised of: 3192 results 
in the Embase database, 2029 in all MEDLINE databases, 2344 in PsycINFO 
database, and 1991 in Journals@ Ovid Full-Text database. Because the combined 
num-ber of articles across all selected databases (9556) exceeded the 6000 limit 
allowing for deduplication, Further deduplication limited the number of articles to 
3061. 
Next, the filters «Human», «Adult» and «Depression» were applied, leaving 570 
articles for title/abstract screen. For the full-text screen, we included original studies 
assessing the functional elements of the HPA-axis in samples including at least one 
of the following phenotypes: melancholic depression, endogenous depression, en-
dogenomorphic depression, atypical depression, their characteristic traits (such as 
«reversed neurovegetative symptoms»), and a comparison group. 
After the title/abstract screen, 247 articles were retrieved for a full-text screen.
The criteria for inclusion in the review were:
    a) The inclusion of adult patients diagnosed with major depressive episode 
according to DSM or ICD operational criteria; 
    b) An explicit description of criteria for melancholic and/or atypical depressive 
subtype identification in patients/ or precise description of symptom sets 
characteristic of melancholic/atypical subtype (e.g. reversed neurovegetative 
symptoms)
    c) The evaluation of the levels of basal and/or post-challenge cortisol in the blood, 
saliva, urine or CSF, of basal and/or post-challenge ACTH in blood, and of basal 
and/or post-challenge CRF in blood or CSF. 
Studies were excluded if:
a) They had no comparison group (e.g. studies in a small sample of melancholic 
patients before and after TMS, however, studies which compared the subtypes be-
tween each other without healthy controls, were included)
b) They addressed other neuroendocrine outcome measures  (e.g. NE, Prolactin, 
Vasopressin) - unless they also assessed HPA-axis measures. Here it is important to 
acknowledge that the function of the HPA-axis is largely dependent on, and 
interrelated with, other endocrine factors and the immune system. However, given 
the focus of this review, measurements other than those directly related to the HPA-
axis were not considered. 
The details of the literature search have been structured using the Prisma Flowchart 
in Fig.1
Fig.1 PRISMA Flow Diagram
Results
The final stage of the search process yielded 48 articles in general. The studies were 
subdivided into four groups:
Group 1. Studies (n=27) which compared «melancholic» (or other definitions) 
depression with depression not matching any of the definitions for melancholia, or a 
control group
Group 2. Studies (n=9) which compared «atypical» (or other definitions) depression 
with depressions not matching any of the definitions for atypicality, or a control 
group. 
Group 3.  Studies (n=7) which compared «melancholic»  (or other definitions) 
depression with «atypical» (or other definitions) depression. 
Group 4. Studies (n=5) which employed a longitudinal design.
The results for each section are summarized in Tables 1-4, respectively
INSERT TABLE 1
Melancholic studies
The group comparing various definitions of melancholic depression with non-
melancholic depression or controls included 27 studies. For clarity and simplicity, we 
suggest that within the group, these studies further be sub-grouped according to the 
measurement of HPA-axis activity used. However, since quite a few of the studies 
addressed more than one potential measure of HPA-axis activity, some of them may 
be mentioned several times both in further text and the tables.
The majority of studies assessing the function of the HPA-axis in melancholic 
depression have focused either on the rates of suppression following 
Dexamethasone Suppression Test (17 studies) or basal cortisol in either blood, CSF, 
or urine (16 studies). Those are followed by basal ACTH (3 studies), basal CRH 
(CRF) (2 studies), oCRH challenge (1 study),  ACTH stimulation (1 study), 
fenfluramine challenge (2 studies), Dex/CRH (1 study).
    Dexamethasone suppression test
    Some of the earliest studies focusing on DST as a potential diagnostic test for 
melancholic depression were performed by B.Carroll et al. This review focuses on 
the 1981 study which lasted for 6 years and included 368 patients. In this study, the 
authors addressed not only the issues of the specificity and sensitivity of DST but 
also proposed the standard procedure, since the methodologies employed by 
various researchers vary markedly in the dose of administered dexamethasone, the 
time of measurement, as well as the threshold for «suppression». The authors 
concluded that the optimal balance between the measures of sensitivity, specificity 
and diagnostic confidence of DST for melancholic depression would be at the 
threshold of the non-suppression set at 5 μg/dL, the dose of dexamethasone set at 1 
mg, and the measurements were taken at 4 pm and 11 pm. The latter had been 
demonstrated in their previous studies which indicated that the abnormalities of the 
HPA-axis are subtle in depression and therefore patients may still be capable of 
normal suppression in the morning hours but fail to do so later in the course of 24 
hours post-challenge (Carroll et al., 1982, further confirmed by Rubin et al., 1987).  
Similar findings were also observed by Rubin et al., (1987), in a study which will be 
discussed further. In general, the sensitivity (defined here and further as the 
proportion of melancholic patients with abnormal DST results) across all values 
varied from 39% to 53%, the specificity (defined here and further as the percentage 
of melancholic subjects in whom normal results were observed) ranged from 85% to 
97%, and the diagnostic confidence, i.e. the proportion of abnormal test results that 
were true-positive for melancholia, from 83% to 93 %.  These results appear rather 
convincing, but an essential aspect of their findings is that for the definition of 
melancholia, they used their operational criteria. 
    Banki et al. (1986), apart from other hormonal challenges, investigated DST 
responses in female patients diagnosed with DSM-III defined melancholic 
depression, and reported that abnormal DST response was observed in 67% of 
melancholic patients, which significantly exceeded the rates for both other 
psychiatric disorders and controls (p<0.05). Evans et al. (1987), reported slightly 
higher rates of non-suppression for DSM-III melancholic depressed patients - 78%, 
however, it is of note that patients with psychotic depression demonstrated an even 
higher proportion of non-suppression (95%), which significantly exceeded that in the 
melancholic group even when non-suppression was defined as >10 μg/dl or >15 
μg/dl. 
    The issue of the threshold for non-suppression was addressed in a study by 
Winokur et al. (1987). The authors looked at the extremities of the DST response: 
having tested 423 patients with a range of affective diagnoses, they split the results 
into two categories: strong suppressors defined as having post-dec cortisol levels 
below 1.5 μg/dl, and strong non-suppressors whose post-dec cortisol was > 6 μg/dl. 
The main results were that melancholic symptoms (defined by DSM-III criteria) were 
significantly associated with non-suppression (24% vs. 9% suppressors, p=0.01). At 
the same time, the diagnosis of secondary depression was significantly associated 
with suppression (38% vs. 19%, p=0.025). It is notable, however, that although there 
existed a significant association of non-suppression with melancholia, there were 
indeed only 24% of NS among all melancholic patients, which may indicate that the 
threshold of 6 mg/dl could be too high to yield sensitive results. (Winokur et al., 
1987).
    Contributing to the debate about the correct classification, or the ability of a certain 
definition of melancholia to identify non-suppressors, Peselow et al. (1992) 
demonstrated that patients who met both DSM-III criteria for melancholia and RDC 
criteria for endogenous depression, showed higher rates on non-suppression than 
those with «neither» subtype and controls, but not compared to those with «either 
of» the subtypes (Peselow et al., 1992). Paslakis et al. (2011) also used DSM-IV 
(SCID-validated) criteria for melancholia, and although they did demonstrate a 
significant difference in suppression levels between melancholic depressed patients 
and controls, both the mean effect size and the sensitivity of the test proved low 
(Paslakis et al., 2011). Interesting results, although in a very small number of 
patients (n=5 patients with "rapid improvement") were obtained by Barocka et 
al.,(1987). They showed that the clinical course of "rapid improvement» was 
significantly associated with normal suppression in the DST even in endogenous 
patients (p = 0.04). They suggested that by eliminating those patients who show a 
rapid improvement shortly after the test, the test sensitivity for endogenous 
depression could be increased by about 10%, while the specificity remains constant 
(Barocka et al., 1987).
    Rubin et al. (1987) addressed the response to DST (with a threshold set at ≥ 3,5 
μg/dL), in 40 patients with a definite RDC diagnosis of endogenous depression vs. 
40 age-matched controls. Interestingly, even with this low a threshold, they only 
observed non-suppression in 15 of the 40 depressive patients, which, however, was 
significantly different from controls, yielding a sensitivity of 38% and a specificity of 
88%. Their key observation was the melancholic patients who differed from each 
other of DST suppression rates were also different on some other HPA-related 
characteristics. At the same time, the suppressors did not differ from control subjects 
in any of the measures.
    Related findings were reported by Amsterdam et al. (1989) who performed a 
complex study in two consecutive samples, employing a range of challenge tests. 
Tests other than DST will be discussed in the relevant section. Consistent with the 
results obtained by Rubin et al.,(1987) they found that the subgroup of melancholic 
patients who were DST non-suppressors demonstrated larger mean cortisol values 
for all of the response measurements compared to the other patient subgroups or 
healthy controls, and to all the other patient groups combined. Also, the melancholic 
DST-NS subgroup showed a skew toward larger overall cortisol response values, 
rather than the standard distribution of the healthy controls, indicating that this group 
of patients had members with particularly enhanced adrenocortical responsiveness. 
Besides, maximum cortisol response to ACTH was significantly decreased after 
treatment in the MEL/DST-NS group (p=0.04). Consistent with the conclusions made 
by Rubin et al., the authors inferred that the subgroup of DST-NS patients with 
melancholic features might represent a diagnostically homogeneous subpopulation 
who are more likely to demonstrate endocrine abnormalities at several sites within 
the HPA axis (Amsterdam et al. 1989).
        However, there were studies that did not show a strong association between 
the diagnosis of endogenous depression and endogenicity.  Hubain et al. (1996) 
performed DST in a large sample of 155 Newcastle Endogenous Depression 
Diagnostic Index (NEDDI) - defined endogenous patients vs. a similar number of 
non-endogenous patients. Authors failed to find any association, at a suppression 
threshold of 50 μg/l (i.e. 5 μg/dL). (Hubain et al., 1996). Berger et al. reported results 
both for the common ≥ 5 μg/dl threshold and for ≥ 8 μg/dl ( a result that yielded 2.7% 
in a healthy sample). In their study, in three separate patients samples including the 
diagnosis of a) endogenous (+schizoaffective) depression, b) neurotic and situational 
depression and c) other psychiatric diagnoses, a positive DST failed to yield 
predictive value over 40-60%, indicating that only one of two patients with positive 
DST would suffer from endogenous depression. For subtyping, authors used three 
instruments: ICD-8, RDC and Newcastle Scale (Berger et al., 1984). 
    Particular attention should be paid to studies which focused not, or not only, on 
subtypes as a whole, but also on individual symptoms which reflect the more «biolo-
gical» manifestations of depression. For instance,  Miller and Nelson (1987) 
investigated the DST response in 95 depressed inpatients, 45 of them melancholic 
according to DSM-III criteria (although they also used RDC criteria which did not 
contribute much to the variance apart from a slight difference in p-values). However, 
they assessed the association of individual symptoms, not subtypes as a whole, with 
suppression rates. They demonstrated that with a threshold for non-suppression of 7 
μg/dL (which is obviously higher than in general), the four factors most strongly 
associated with DST non- suppression were initial insomnia, loss of sexual interest, 
agitation, and weight loss. Factors associated significantly yet with a small effect size 
were also retardation and when cortisol levels were assessed as a continuous 
variable, ruminative thinking and midnight awakening. It is, nevertheless, notable that 
the four strongly associated factors were only shown to account for 24% of the 
variance. In a study by Berger et al., despite low predictive value observed,  weight 
loss was shown to enhance the rate of abnormal DST results in psychiatric in-
patients, regardless of their diagnostic classification (Berger et al., 1984). 
    Casper et al. (1987), also focused on neurovegetative symptoms of depression 
rather than defined subtypes. They assessed basal and post-DST cortisol levels in 
28 patients diagnosed as having MDD and presenting with either marked weight 
loss, appetite loss, or both. Although both weight loss and appetite loss were 
significant predictors of elevated basal cortisol levels, non-suppression, defined as 
cortisol levels above or equal to 6 μg/dL, was only significantly associated with 
weight loss. Interestingly, as will be discussed in the relevant section, in another 
study comparing MDD patients with hypersomnia and/or increased appetite/ weight 
with MDD patients without these symptoms or controls did not reveal a strong 
association between reversed vegetative symptoms and HPA-axis function: the most 
significant association was demonstrated for DST non-suppression in MDD patients 
without hypersomnia or weight/appetite increase vs. the opposite or controls (Casper 
et. al., 1988). Another study focusing on individual symptoms was that by Maes et al. 
(1989), who distinguished between vital vs. non-vital symptom clusters instead of 
MDD subtypes, and they as well demonstrated that higher levels of cortisol post-DST 
were associated with sleep and appetite disturbances. 
    At the same time, Orsel et al. (2010) performed a cluster analysis and identified an 
endogenous cluster which differed from non- endogenous on the following 
characteristics: anorexia/weight loss; diurnal variation, depressed mood, loss of 
energy, early morning awakening, loss of interest, suicidal ideation, distinct quality of 
mood, cognitive disturbances, psychomotor disorders, psychotic symptoms, non-
reactivity, feelings of guilt, and sleep disorder. However, of the 14 SCID-I items, only 
six factors - early morning awakening, distinct quality of mood, feelings of guilt, non-
reactivity, suicidal ideation, and psychomotor disorders - were significant 
discriminators between the clusters. The clusters showed a high degree of 
correlation with DSM-IV melancholic and non-melancholic depression, respectively, 
although they were not a complete 100% match. The authors were able to 
demonstrate a significant difference in basal cortisol levels between endogenous and 
non- endogenous clusters, as well as in rates of DST suppression (≥ 3.5 μg/dl 
threshold), however, not in post-DST cortisol measured as a continuous variable. 
Moreover, rather unusually, in studies discussed above, only mood reactivity as a 
single symptom differed significantly between suppressors and non-suppressors (i.e. 
non-reactivity correlated with non-suppression; Orsel et al., 2010).
    Finally, important observations regarding the role of phenotype in HPA-axis 
assessment in depression can be inferred from a study by Halbreich et al., 1989, 
who compared patients with RDC Endogenous Depression and DSM-III PTSD with 
RDC MDD-ED patients alone and controls. They demonstrated that the presence of 
a diagnosis of PTSD determined a significant difference in DST response in patients: 
all PTSD-ED patients proved to be suppressors (not different from controls – 
however, suppression threshold wasn’t specified in the article, except for mean 
values of post-DST cortisol which were at mean of 3,72 in MDD-ED patients 
compared to 0,96 in PTSD-ED patients, p=0.01) and had lower basal plasma cortisol 
levels compared to MDD-ED patients (Halbreich et al., 1989).
Other challenge tests
Amsterdam (1989) attempted to assess several levels of the HPA axis and their 
abnormalities in hormonal response in depressive patients. In their paper, they 
referred to 2 studies which used ACTH as a hormonal challenge. The first one 
compared 16 patients with a depressive disorder (of which, 9 had melancholic 
features) and 11 healthy controls. They found no difference in cortisol levels at 
baseline between groups. However, after ACTH administration, the depressive group 
had a larger increase in cortisol concentrations than controls (p<0,02). Further, the 
authors tried to replicate these results in a larger sample of 72 depressed patients (of 
which 51 had melancholic features) compared to 34 healthy controls and were 
unable to find the same results. In contrast, they found that both at baseline and after 
ACTH administration, cortisol levels did not significantly differ between groups. The 
same article cites a study with ovine CRH challenge. They administered oCRH to 26 
depressed patients (of which 14 had melancholic features) and compared to 11 
healthy controls. They found no difference between groups in cortisol levels at 
baseline and after challenge; nonetheless, depressive patients as a group had lower 
ACTH response compared to controls. The effect was larger in patients with 
melancholic features (Joseph-Vanderpool et al 1991). 
The study by Mitchell et al., (1990) tried a different challenge using the serotonin 
agonist Fenfluramine 60 mg but found no difference between groups of 
“endogenous” vs. “non-endogenous” depressive patients. The 30 patients in the 
study were evaluated with four different types of criteria (DSM-III, ICD 9, RDC, 
Newcastle criteria) to divide subtypes; however, they did not found differences in 
post-challenge cortisol levels between any of the groups. 
Another study that used a similar compound, in this case, d-Fenfluramine 30 mg, al-
so failed to show any significant difference. The study compared 23 depressive 
patients with 16 healthy controls and found that both groups had the same levels of 
cortisol after challenge (O'Keane & Dinan, 1991). 
In 2011, Paslakis (Paslakis et al., 2011) compared 3 ways of assessing HPA axis 
and their relevance for detection of depression. One of those was the Dex/CRH test. 
They found that the test had low levels of sensibility (30,8%) and moderate 
specificity (78,8%) being the worst marker between the three compared (DST, 24h 
cortisol).  
Basal measurements
Basal cortisol
The search identified 19 studies which compared the basal cortisol levels (either as 
part of further DST or separately) among patients diagnosed with melancholic 
depression and matched controls and/or non-melancholic depressed patients.
    Rubin et al. (1987) demonstrated that the elevation of basal cortisol when 
measured continuously over 26 hours correlated most significantly with the DST 
status of the patients: i.e. patients that were non-suppressors had elevated 24-hour 
cortisol and nocturnal cortisol nadir compared to both controls and patients who were 
suppressors. This was shown in a sample of RDC-examined definite endogenous 
patients (Rubin et al., 1987).
    Further evidence of the increase in basal cortisol levels between melancholic 
depressed patients and controls/non-melancholic patients comes from studies by 
Gue-chot et al. (1987), Wong et al. (2000), Paslakis et al. (2011), O’Keane and 
Dinan(1991). Guechot et al. performed a simple one-time salivary test of cortisol at 
11 pm in patients diagnosed as «primary» depressive using DSM-III and Saint-Louis 
criteria, compared to both secondary depressives (p<0.05) and controls (p<0.02). 
They also reported high sensitivity (62,5%) and specificity (75% vs. secondary 
depressives, 90% vs. controls) rates of the test for the identification of primary 
depressive patients when the cut-off was set at 3.45 nmol/l (Guechot et al., 1987). A 
study by Wong et al. (2000), addressed multiple measures including basal plasma 
cortisol in patients with a DSM-II-R and RDC-defined melancholic subtype of 
depression and controls, concluded that mean 30-h plasma cortisol levels in 
depressed patients were significantly higher vs. controls. Paslakis et al. (2011), 
together with DST and Dex/CRH, which will be discussed, further, performed a 
comparison of Basal cortisol levels in melancholic patients defined using DSM-IV 
criteria vs. healthy controls. They confirmed that diurnal basal cortisol secretion as 
measured throughout 24 hours, is significantly higher than in controls, as measured 
both by cortisol profile graphs and area under the curve (p=0.001 and p<0.01, 
respectively). The maximum of variation was observed at 11.30 and 14.00. In this 
study, basal cortisol was the most sensitive marker for melancholic depression than 
DST, and at the time interval from 10.00 to 12.00 yielded results with optimal 
sensitivity (83.3%) and specificity (87.9%). O’Keane and Dinan (1991) study also 
reported elevated baseline cortisol in patients diagnosed with DSM-III-R major 
depression and Newcastle scale criteria for endogenicity. They showed a significant 
increase in basal cortisol in patients compared to controls subjects.  CORE measure 
was also used by Liu et al.(2016) in the definition of melancholic depression. They 
performed an analysis of 228 blood metabolic markers in 21 melancholic patients (as 
well as 58 patients matching criteria for «anxious depression» defined by one or 
more comorbid anxiety disorders on M.I.N.I, and 100 controls). One of the important 
outputs of this study was the confirmation that melancholic depression can represent 
a more biologically distinct subtype of depression. Regarding HPA-axis activity, 
increases in basal cortisol levels were significant for the melancholic group, as well 
as increases in other metabolites in the hormone biosynthesis pathway 
(androstenedione and corticosterone; Liu et al., 2016). 
Michopoulos et al. (2008) studied whether elevated HPA-axis function was 
associated with executive dysfunction and memory deficits in melancholic (as 
defined by DSM-IV-TR criteria) depressed patients. They also reported no significant 
difference between plasma and salivary cortisol levels in melancholic vs. none- 
melancholic groups. The only significant correlation between cortisol values and 
CANTAB tests, either mnemonic or prefrontal, used for cognitive function 
assessment was an association between morning salivary cortisol and the ID/ED 
total errors. 
    In accordance, Mitchell et al. (1990) and Joyce et al. (2002) compared a range of 
basal measures in patients with melancholic depression defined by several criteria. 
Mitch-ell et al. compared such diagnostic systems as ICD-9, DSM-III, RDC and 
Newcastle Scale melancholic/endogenous phenotypes, while Joyce et al. (2002) 
compared DSM-IV based diagnose of melancholia with that focusing on CORE 
measures.  In the second study, there was a significant correlation with basal 
cortisol: in male patients defined as melancholic by CORE criteria.
    A few studies mentioned above about DST results also assessed the association 
of basal cortisol levels with particular symptoms. Casper et al. (1987) reported that 
basal plasma cortisol was significantly associated with weight and appetite loss; 
Kaestner et al. (2005) indicated that high baseline cortisol levels correlated with 
HAM-D severity and the presence of weight loss. 
Basal ACTH 
    There were three studies which addressed basal ACTH levels, of which none 
indicated elevated plasma ACTH levels in melancholic patients.
Wong et al. (2000) who used both DSM-III-R and RDC criteria to define the 
melancholic subtype failed to find a significant association in the 
melancholic/endogenous group with elevated basal plasma ACTH; however, since 
they ob-served elevated cortisol levels, they also reported that plasma cortisol-to-
ACTH ratio was significantly elevated in melancholic patients compared to controls. 
Similarly, Joyce et al. (2002) failed to show elevated ACTH in melancholic patients 
when applying either DSM-IV or CORE criteria. Finally, Gomez-Gil et al.(2010) got 
their negative results when applying the NEDDI criteria.
    Basal CRF
There were two studies which reported basal CRF levels. Wong et al. found that 
melancholic patients did not differ from controls in their levels of basal CRF which 
was disproportional about elevated basal cortisol. Similarly, Joyce et al. (2002) failed 
to demonstrate elevated basal CRF using either DSM-IV or CORE definitions. 
INSERT TABLE 2
Atypical vs non-atypical or controls
We selected nine studies focusing on the atypical depressive subtype or its 
characteristic features. Among this group, we indicated: studies focusing on DST 
(n=4), studies assessing basal cortisol either in blood, urine, or the CSF (n=7), one 
study assessing basal ACTH levels (n=1), two studies using desipramine stimulation 
(n=2), a study using dextroamphetamine stimulation (n=1); a study using oCRH 
stimulation (n=1).
Dexamethasone Suppression Test (DST)
   
Of the four studies assessing dexamethasone suppression rates in atypical patients, 
only two used standard DSM-based criteria.
Levitan et al. (2002) evaluated DST response in 8 female patients with DSM-IV-
defined atypical MDD vs. 11 healthy controls and demonstrated that atypical patients 
had higher rates of suppression vs. controls (91,9% suppression in atypical 
depressive patients vs. 78,3% in controls). However, it is notable that the authors 
used a lower dose of dexamethasone than usually administered: they used both 0.25 
and 0.5 mg dosages, and significant results were reported with the latter (Levitan et 
al., 2002). 
Stewart et al. (2005) suggested stratifying patients into late/nonchronic atypical and 
early/chronic atypical subtypes. Patients with early/chronic atypical had significantly 
lower mean 3 h afternoon cortisol levels and 4:00 p.m. post- dexamethasone cortisol 
levels than compared to late/nonchronic atypical (Stewart et al., 2005). This indicates 
that the course of illness may also play an important role in the function of the HPA-
axis and that it may also contribute to the heterogeneity of atypical depression. 
However, since the study had no control group, it is difficult to draw conclusions as to 
whether there is hypocortisolism in atypical patients compared to controls. 
Casper et al., (1988) focused on somatic symptoms such as hypersomnia (n=23) 
and overeating (hyperphagia, n=22), looking at these two symptoms separately, with 
n=15 out of the 22 patients with hyperphagia also demonstrating weight gain, all 
measured by SADS. The groups were compared with MDD patients who exhibited 
neither of the symptoms and with matched controls. The study did not demonstrate 
any increase in DST response in hypersomnia/overeating patients. However, it is an 
important observation that patients with atypical features did not differ from controls. 
In patients presenting with hypersomnia, there were significantly higher rates of 
normal suppression than in «non-atypical» patients, and the latter was similar to 
controls. 
Thase et al. (1989) compared a subgroup of bipolar depressed outpatients with 
«anergic» depression which they defined using own operational criteria as 
manifesting with «anergia» (score 2 on Hamilton scale item 13), «psychomotor 
retardation» (score of 2 or more on item 8), and «reversed vegetative symptoms» 
where weight gain was defined as an increase in weight of 2.2 kg or more, and 
hypersomnia as increase of 1 hour or more compared to normal sleep duration). The 
authors focused on identifying EEG disturbances and DST response in those 
patients compared to controls. Only 3 (13%) of the patients were non-suppressors, 
even considering the somewhat lower threshold for defining non-suppression 
(4mg/dl vs. the more common 5 mg/dl). Likewise, only 6 of the patients had baseline 
cortisol levels higher than 15 mg/dl. Authors also demonstrated that patients, and 
particularly 6 patients with hypercortisolism, had decreased REM latency values. 
Other challenge tests
Two of the studies assessed the levels of cortisol following a challenge test with 75 
mg desipramine.
 Asnis et al. (1995), compared a group of 17 patients diagnosed as suffering from 
atypical depression to 55 patients not matching atypicality criteria. The criteria for 
atypicality were similar to those of DSM-IV, except only one of symptoms additional 
to mood reactivity (hypersomnia, hyperphagia, leaden paralysis, or rejection 
sensitivity) was obligatory for the diagnosis instead of two. It is striking how different 
the phenotypes of patients included in this study could be compared to those 
mentioned above. Patients were compared on their response to 75 mg of 
desipramine, which is a challenge test for noradrenergic function. Although basal 
cortisol levels did not differ significantly between groups, post-DMI cortisol was 
significantly higher in atypical group vs. non-atypical, which suggests that this group 
may have a less impaired noradrenergic system compared to MDD patients without 
atypical features. 
McGinn et al. (1996) studied patients from the same cohort as Asnis et al.(1995). 
However, they stratified patients as having mood reactivity alone (n=29), having 
depression with atypical features as defined by mood reactivity plus one of the four 
atypical symptoms (n=33), and MDD not matching atypical criteria (n=52). The main 
conclusion of the study was that AD patients, similar to the previous study, had a 
significantly higher cortisol response to DMI. 
Apart from DST, Stewart et al. used dextroamphetamine challenge in their sample. 
The difference in post-dextroamphetamine cortisol levels did not reach statistical 
significance although there was a trend for higher numbers in the early/chronic 
atypical group (Stewart et al. 2005). 
Finally, Joseph-Vanderpool et al. (1991) examined HPA-axis function in patients with 
seasonal depression characterised by atypical features such as reverse vegetative 
symptoms. The authors used a challenge test with oCRH, which did not discriminate 
between the subjects and controls. ACTH response to oCRH was delayed and 
reduced in Seasonal Affective Disorders patients.
Baseline measures
Baseline cortisol levels were assessed in seven studies in the group, while basal 
ACTH was only mentioned in one study. 
    Both Asnis et al. (1995) and McGinn et al. (1996) who reported basal cortisol 
levels in ADDS-assessed atypical depressive patients showed no difference be-
tween the patients and controls. Joseph-Vanderpool et al. (1991) reported a trend 
towards lower basal cortisol in SAD patients vs. healthy controls which, however, 
was only significant at 22.00. 
Studies that applied DSM-IV criteria showed slightly differing results. Anisman et al. 
(1999), compared 31 atypical MDD with 14 non-atypical MDD and 15 atypical dys-
thymic with 14 non-atypical dysthymic patients, assessing among other markers, on 
basal cortisol and ACTH levels, and demonstrated significantly decreased basal cor-
tisol, but increased ACTH levels in atypical patients vs. controls. 
Stewart et al. (2005) who also used DSM-IV criteria in their comparison of atypical 
depression with various courses demonstrated that Patients with early/chronic atypi-
cal had significantly lower mean 3 h afternoon cortisol levels (Stewart et al, 2005).
Finally, Casper et al. (1988) and Levitan et al.(1997) used reversed vegetative symp-
toms as criteria for atypicality. The former showed no differences in any of the 
measurements - i.e. plasma, CSF or urinary cortisol,and controls. At the same time, 
Levitan et al. (1997) demonstrated a significant negative correlation between the 
symptoms of hypersomnia and carbohydrate craving and basal cortisol values
TABLE 3
Atypical depression vs melancholic depression 
Studies directly comparing the function of the HPA-axis in melancholic vs. atypical 
depression are rather scarce. Practically, our search only yielded seven relevant 
articles. Of them, the majority (n=5) focused on baseline cortisol measures. There 
were two studies that assessed basal ACTH as well, one study that assessed DST; 
and one study that applied Dex/CRH test. The results of the studies are summarised 
in Table 3 below. 
Challenge tests    
    The correlation between personality disorders, depression subtypes, and DST 
suppression rates was studied in 50 patients by Fountolakis et al.(2004). The au-
thors reported the results of DST in 14 atypical patients and 16 melancholic patients 
defined by DSM-IV criteria. Other groups of patients included those with a «somatic 
syndrome» as defined by ICD-10 (n=32, partly overlapping with atypical and melan-
cholic groups) and 9 patients without a clearly defined phenotype. The authors did 
not observe any significant correlations between DST suppression rates with any of 
the phenotypes; however, the largest proportion of non-suppression was observed in 
the atypical group (42,85%), what goes against our previous described findings. 
They also demonstrated the accumulation of cluster B personality disorders in the 
atypical group, although that was not significant. The possible limitations of this study 
are a small sample size and, possibly, the lack of healthy control group (Fountolakis 
et al., 2004).
    An elaborate study of stress reactivity patterns was performed by Heinzmann et 
al. (2014). This study primarily focused on mice divided into three phenotypes based 
on their stress response patterns; its second stage involved human partici-pants. 
Unlike previous studies, the main criterion of patient grouping was not their 
depression subtype, rather, patients were divided into high (hHR), intermediate (hIR) 
and low (hLR) responders according to their cortisol response in the Dex/CRH test. 
Although authors did not identify patients as having particular depressive subtypes, 
they applied HDRS subscale of non-atypical depression symptoms. Patients in the 
hLR group showed less sleep disturbance, less appetite loss and less weight loss 
than hHR patients. At the same time, hHR patients showed a strong trend towards 
higher ‘agitation’ scores and increased active stress-coping behaviour compared to 
hLR patients (Heinzmann et al. in 2014). 
Basal cortisol and ACTH measures
    The first study to compare the basal measures between the two subtypes was a 
study by Elizabeth Young et al. (2001). Authors investigated the whether cortisol 
secretion reflects a central CRF dysregulation or represents altered adrenal gland 
function. Over a period of 24 hours, ACTH and cortisol levels were assessed at 10-
min intervals in a sample of 25 premenopausal women and 25 healthy controls. Re-
garding depression subtyping, compared patients meeting RDC criteria for endoge-
nous depression (n=6) with patients meeting DSM-IV criteria for atypical depression. 
They found no significant differences in either mean 24-hour plasma cortisol or uri-
nary cortisol secretion between groups, including between patients and controls, alt-
hough mean cortisol values tended to be higher in endogenous group vs. controls. 
Regarding ACTH, the only significant findings were those regarding basal ACTH, 
which was significantly increased in depressed patients in general vs. controls, and 
so was the AUC for basal cortisol. No other significant differences were identified. 
The obvious drawback of the study was essentially the small sample size which 
comprised only 6 and 7 patients in phenotypes of interest. 
Brouwer et al.(2005), recruited a bigger total sample (n=113) of MDD patients. 
However, the numbers of patients meeting DSM-IV criteria for atypical or melanchol-
ic depression were relatively low (32 and 25 patients). The authors analyzed an ar-
ray of endocrine measures including serum and urinary cortisol levels. In subtype 
analysis, only serum cortisol was significantly lower in atypical depressed patients 
vs. those not matching either subtype. 
    Karlovic et al. (2012) compared DSM-IV defined 23 melancholic depressed 
patients, 23 atypical depressed patients and 18 healthy controls on the levels of 
serum cortisol (following a single morning blood test). The authors demonstrated a 
sig-nificant difference between melancholic and atypical subtypes in the levels of 
morn-ing cortisol, where the melancholic group showed an increased cortisol level 
while the atypical group was not different from controls. 
    Cizza et al. (2012), recruited 89 female patients from the POWER (Premeno-
pausal, Osteoporosis, Women, Alendronate, Depression) having reported a depres-
sive episode in the past 3 years. According to DSM-IV criteria, 51 patients had mel-
ancholic depression, 16 presented with atypical features, and in 22, no subtype crite-
ria were met. The 24-hour sampling of plasma ACTH and cortisol yielded no signifi-
cant difference in 24-hour cortisol plasma cortisol between groups. However, plasma 
ACTH was significantly higher in the atypical subtype vs. the control group (F (1, 83) 
= 4.01, p<0.05) vs. controls. A group by time interaction demonstrated that ACTH 
was elevated in the atypical group only in the daytime, with greatest differences ob-
served from 10 AM to 5 PM. Besides, after adjustment for total body fat, the mean 
24-hour adjusted log leptin value was elevated in the melancholic subgroup, as 
compared with controls (Cizza et al. 2012). 
    The biggest patient sample analyzed so far was that recruited by Lamers et al., 
(2012), from the NESDA cohort. Authors compared some inflammatory, metabolic 
markers, saliva cortisol awakening curves, and diurnal cortisol slope in 111 chronic 
depressed patients with melancholic depression and 122 patients with atypical 
depression. However, their labels did not refer to DSM classifiers, rather to results of 
a latent class analysis performed using CIDI questionnaires, which showed no 
significant effect of the measure of mood reactivity or interpersonal sensitivity, but a 
robust effect of weight and sleep characteristics. In attempts to make the study more 
homogenous, the authors included only chronic severely depressed patients, as this 
category showed the most stable patterns of depressive symptoms. They 
demonstrated that the atypical subtype differed from the melancholic subtype on a 
whole range of symptoms, including area under the curve on the ground (AUCg) and 
diurnal cortsol slope measures (decreased in the atypical group) (Lamers et al., 
2012). 
Longitudinal studies
    It is of note that due to a range of factors, and first of all the complexity of the 
tests, there is a substantial lack of studies assessing the function of the HPA axis 
across both phenotypes of interest longitudinally. Our search yielded only 5 articles 
which used a longitudinal design. The first study found with the search terms was 
that by R.G.Haskett et al. (2005), where the authors assessed the changes in the 
DST response across several weeks in hospitalized patients. This methodology was 
grounded in the previous observations that depressed patients who completed a 
DST on day 2 of hospitalization had a higher frequency of cortisol nonsuppression 
(71%) than depressed patients who were tested on days 3-6 (33%; Coccaro et al., 
1984). The study demonstrated that although there was an overall decrease in the 
rates on non-suppression in both the patients with endogenous depression and 
control subjects (from 55 to 36%), this was mostly accounted for by the difference in 
the control group, while the sensitivity of the test for the endogenous depressive 
patients did not change significantly (Haskett et al., 1987).
    In 1997, Steiger et al. performed a study assessing the levels of basal plasma 
cortisol in 12 endogenous depressive patients diagnosed using RDC criteria on ad-
mission and post-treatment. They demonstrated that in ED patients, plasma cortisol 
was significantly elevated on admission compared to healthy controls, and that it was 
also significantly reduced after treatment, indicating that elevation was specific to 
acute endogenous depression. 
     A study by Kaestner et al (2005) also employed a longitudinal design - pa-tients 
were assessed on admission (t1) and after treatment, in remission (t2). The study 
focused on assessing a range of factors, basal including basal cortisol and ba-sal 
ACTH, in unmedicated, acutely depressed melancholic patients (n=37) compared 
with 37 controls. They demonstrated that on admission, both cortisol and ACTH were 
elevated in melancholic patients compared to controls, but not when compared with 
non-melancholic patients. Plasma ACTH was still increased in melancholic patients 
in remission compared to controls. At the same time, cortisol was elevated in acutely 
depressed melancholic patients only, but not in remitted ones (Kaestner et al., 
2.005).
Pintor et al, 2013, measured ACTH and cortisol response using synthetic 
human CRF challenge in relapsing, non-relapsing and partially relapsing patients 
with DSM- IV melancholic depression over a follow-up period of two years. In terms 
of the overall comparison of depressed and healthy groups, significant differences 
were observed for post-CRF ACTH, cortisol levels and for area under cortisol curve 
between healthy controls and the three groups of melancholic patients.
    Finally, the only article assessing the longitudinal course of HPA-axis 
abnormalities in atypical depression is that by Geracioti et al., 1992, and represents 
a case study of a female patient diagnosed with atypical depression across 6 
months. The results obtained by the authors correspond with the notion that atypical 
depression has a different pattern of abnormalities: the patient was eucortisolemic in 
an acute phase of depression, and further cortisol levels showed a negative 
correlation with a deterioration of depressive symptoms. 
Discussion
The key problem in diagnosis is the fact that elaborate classification systems that 
exist today are solely based on subjective descriptions of symptoms. Such detailed 
phenomenology includes the description of multiple clinical subtypes; however, there 
is no biological feature that distinguishes one subtype from another. Integrative 
approaches to understanding complex health issues can transcend disciplinary and 
knowledge boundaries and provide opportunities to view phenomena from diverse 
perspectives. A future diagnostic criteria system in which aetiology and 
pathophysiology are essential in diagnostic decision-making would bring psychiatry 
closer to other specialities of medicine (Juruena et al. 2007). Thus, the heterogeneity 
of clinical conditions encompassed under the concept of major depression seems to 
be one of the limiters of these advances. Therefore, the identification of distinct 
subtypes of depression may allow advances in these areas by allowing the 
identification of more homogeneous groups of patients, both in clinical aspects and 
in those related to the aetiology and pathophysiology of the disorder presented. This 
depends on many factors like severity and type of depression, genotype, and history 
of exposure to stress, temperament, and probably resilience (Mello et al., 2007) 
The analysis of the articles focusing on the differences in the function of the HPA-
axis depending on depressive subtype has revealed a range of sufficient pitfalls in 
research methodologies. In this sense, although the concept of a melancholic 
depression subtype, equivalent to the concepts of endogenous or psychotic 
depression, has a long history of psychiatry and is well defined (Sullivan et al., 2002, 
Baumeister & Parker, 2012). The atypical subtype, in turn, encompasses a 
heterogeneous group of patients and has only recently been introduced into the 
DSM-IV as a specifier. Moreover, although the literature has given extensive support 
to the validity of depression with atypical features as distinct from melancholia and 
depression without atypical or melancholic features, there is still a certain degree of 
disagreement among researchers about which particular symptoms constitute this 
specifier, and whether such factors as mood instability and interpersonal sensitivity 
have the same weight in the dichotomy as biological reversed vegetative symptoms. 
Thus, the lack of well-defined diagnostic criteria to characterize these subtypes of 
depression is reflected in the diversity of nomenclatures used in the literature to 
define these subtypes.
In this sense, in this systematic review, we find a significant variation in the terms 
used in the articles to define the melancholic and atypical subtypes. Besides the 
variation in definition, a major complication is presented by the variation in 
approaches to challenging tests (e.g. dosage, time of response measurement and 
threshold used to defining non-suppression), and the variety of classifications used 
in order to define «melancholic» or «atypical» subtypes complicate the task of 
arriving at a steady conclusion.
    Recently we have published a systematic review comparing the 
neuropsychological performance of melancholic patients to non-melancholic 
depressive patients), including atypical depressives, and healthy controls (Bosaipo et 
al. 2017). In this study, the findings suggest that melancholic may have a distinct and 
impaired cognitive performance compared to non-melancholic depressive patients 
on tasks involving verbal and visual memory, executive function, maintained 
attention and span, as well as psychomotor speed, this last mainly when cognitive 
load is raised (Bosaipo et al. 2017).
Besides, although the literature is increasingly demonstrating distinct differences in 
clinical, biological, anatomical and response to treatment characteristics be-tween 
these two subtypes of depression, this debate is still ongoing. In this sense, the HPA 
axis play a vital role in the distinction between these subtypes, since stressful life 
events play a major role in the pathogenesis and onset of depressive episodes 
(Kendler et al., 2002). According to some authors, stress could lead to the onset of 
the first depressive episode in genetically vulnerable individuals, making them even 
more sensitive to stress in a fast forwarding fashion, compatible with the kindling 
hypothesis by Post (1992). With this, the individual would need less stress to trigger 
new crises, and it would become more vulnerable to the reprint of new depressive 
episodes before different, sometimes milder, stressors (Post, 1992). Also, adverse 
experiences in early life have been associated with significant increases in the risk of 
developing depression in adulthood, particularly in response to additional stressors 
(Tofoli et al. 2011; Cohen et al., 2001; Juruena, 2014). Thus, as the HPA axis is 
activated in response to stressors, changes in the functioning of this axis, at any 
level of its components, and its regulations may play a pivotal etiological role in the 
onset of depressive disorders (Holsboer, 2000; Tyrka et al., 2008).
Among the studies included in this systematic review that evaluated patients with 
melancholic depression, most (n=17) studies focused on DST response. Of them, 
the vast majority did indicate significantly elevated degrees of non-suppression in 
melancholic patients.
    Nevertheless, there have been two studies, which did not demonstrate this 
significant association. The one Hubain et al. (1996), who performed DST in a large 
sample of 155 Newcastle Endogenous Depression Diagnostic Index (NEDDI) - de-
fined endogenous patients vs. a similar number of non-endogenous patients, in fact, 
did initially show was a statistically significant difference in the dexamethasone 
suppression test response at 1600 h, but when the effects of age and severity of 
depression were controlled, those differences disappeared. In a study by Berger et 
al.(1984), the majority of comparison groups were other psychiatric patients, which 
somewhat complicates drawing conclusions about the melancholic-nonmelancholic 
dichotomy, however, this study showed the importance of biological symptoms such 
as weight loss as a factor in non-suppression, confirming the notion that research 
may need to focus more on the vegetative symptoms of subtypes of interest.  
    The inconsistence of results may partly be influenced by different dexamethasone 
doses and suppression thresholds that were used. However, our review has 
demonstrated that the most dramatic differences lie between studies that used 
different approaches to defining melancholic depression. So, when RDC was used 
as a definition scale, those having a diagnosis of endogenous depression showed 
higher non-suppression rates than those with probable endogeneicity. Patients with 
DSM-defined melancholic features tended to show higher non-suppression in 
melancholia, too. It is also of note that strong support of elevated post-dex cortisol in 
melancholic patients comes from the studies which either focused on particular 
symptoms which are characteristic of the melancholic subtype or considered patients 
were meeting more than one diagnostic scale criteria (e.g. both DSM-IV and RDC) or 
used their operational criteria of endogeneicity. Another suggestion made by a few 
authors is that depression characterised both by melancholic features and DST-non-
suppression is, in fact, a distinct form of depression. This inference stems from the 
observations that melancholic patients who are non-suppressors exhibit higher basal 
cortisol levels as well compared to melancholic patients normally responding to DST. 
Also, this increase seems to be associated mainly with melancholic depression with 
psychotic symptoms (Contreras et al., 2007). 
        Evidence of elevated basal cortisol and basal ACTH in melancholic patients is 
much less consistent. Approximately half of the selected studies failed to 
demonstrate differing levels of cortisol in melancholic patients compared to non-
melancholic ones or controls. This may be due to differences in methodology, or 
differences in the diagnosis of melancholia (e.g. RDC definite endogenous criteria 
showed a more consistent association than DSM-III melancholic criteria). Regarding 
ACTH, none of the studies showed alteration in this measurement compared to 
controls. 
However, when studies of melancholia focused on particular biological symptoms 
such as weight loss and appetite loss/insomnia or used their operational criteria for 
endogeneity mainly focusing on vital symptoms, they reported significant increases 
in basal cortisol. This means that there may be a stronger association with biological 
symptoms rather than subtypes as a whole.
    When atypical studies were evaluated, importantly, the majority of those, re-
regardless of the outcome measures, did not show a difference between atypical 
patients and control subjects, although there was a significant difference between 
atypical and melancholic patients. There were indeed studies (Levitan et al., 2002; 
Anisman et al., 1999), which showed significantly decreased post-DST and basal 
cortisol in atypical patients. However, it is important to consider that while Levitan et 
al. (2002) compared atypical patients to healthy controls and their results indeed 
may suggest hypoactive HPA-axis; Anisman et al. (1999) compared patients to non-
atypical depressed patients, which rather indicates the difference with another 
subtype. 
    The studies directly comparing the function of the HPA-axis between melancholic 
and atypical patient groups are scarce and difficult for analysis since their 
methodologies vary largely. In particular, of the 7 studies comparing HPA axis 
functioning between patients with melancholic and atypical depression, only 2 used 
challenge tests (Fountoulakis et al., 2004; Heizmann et al., 2014.). Among them, 
only the one by Heinzmann et al.,(2014) despite a very different design from the rest 
of DST studies observed in the whole review, showed a significant difference 
between sub-types,
    There was no consensus in the studies assessing basal cortisol, while Brouwer et 
al. (2005) and Lamers et al. (2012) did show decreased cortisol levels in atypical 
patients vs. controls and also underline the difference be-tween melancholic and 
atypical groups), others only indicated that they were not different between atypical 
and controls. Notably, the design employed by Lamers et al. (2012) showed no 
significant effect of the measure of mood reactivity or interpersonal sensitivity, but a 
robust effect of weight and sleep characteristics. At the same time, the authors only 
recruited severely depressed atypical patients, which may also have contributed to 
the strength of association.
This systematic review also considered a separate group including only longitudinal 
studies. Although these studies are just a few and are also different in 
methodological aspects, it could be suggested that in melancholic depression, 
elevated HPA-axis function is a state rather than a trait characteristic, i.e. that remit-
ted patients have lower basal and post-challenge cortisol levels compared to acutely 
depressed patients. At the same time, the case study - and the only longitudinal 
study of the atypical subtype - showed a negative correlation between the severity of 
depressive symptoms and cortisol levels, thus supporting the idea of the dichotomy. 
    Thus, although data in the literature seem to confirm that there are distinct 
patterns of HPA axis functioning between the melancholic and atypical depression 
subtypes, further studies with refining and homogeneous methodology are needed to 
characterize this pattern better. These may be attributed to methodological 
differences, including varying challenges and doses and non-suppression 
thresholds, varying availability of cortisol in urine, blood, saliva, or CSF. However, 
mainly the heterogeneity of clinical conditions assessing the same endophenotype 
and incorporated under the concept of major depression seems to be one of the 
limiters of these advances.
    Novel advances in the methodology may shed light on the dichotomy in a more 
precise manner. In particular, there are currently no published studies evaluating hair 
and nail cortisol levels between the subtypes, but a few are underway. Be-sides, 
speaking of challenge tests, among the articles included in this review, the majority 
used the Dexamethasone Suppression Test. However, although the Dexa-
methasone Suppression Test remains widely used and widely studied as a biological 
marker in psychiatry, this test has some limitations because of the pharmacokinetic 
and pharmacodynamic characteristics of Dexamethasone that are very different from 
cortisol. Unlike cortisol, Dexamethasone has low affinity to MR receptors. Therefore, 
these studies allow us to investigate only the functioning of GR receptors in the sub-
types of depression (Pariante et al., 2002; Juruena et al. 2006). Future studies might 
use different challenges, like MR antagonists, such as Spironolactone, MR agonists, 
such as Fludrocortisone, the Prednisolone suppression test, which appears to bind 
to MR as well as GR. MR function, and perhaps more important, MR/GR ratio, 
remains understudied in depressed populations, and it seems like an interesting 
prospect in this area (Juruena et al. 2013).
    In general, this review has provided a rather convincing support for the presence 
of a difference in HPA-axis activity between the two subtypes, melancholic and 
atypical depression, regardless of the classification. However, it is much more 
difficult to conclude whether atypicality is associated with hypofunctional HPA-axis 
and enhanced negative feedback (such as implied in PTSD which was confirmed in 
a study by Halbreich et al..1989), or simply is not different from controls. It may be 
that the severity and the course of atypical depression, as well as the presence of 
particular vegetative symptoms (hypersomnia, weight gain as opposed to 
interpersonal sensitivity), are stronger predictors of decreased basal and post-
challenge cortisol levels. However, this is yet to be established in studies employing 
a more unified efficient methodology.
    The assessment of other factors potentially interfering with the dichotomy is 
outside the scope of this review. However, it should be noted that in the same 
studies which showed conflicting results regarding hypocortisolism in atypical 
depression, there was a much stronger association with elevated inflammatory 
factors (Lamers et al., 2012). This has driven a novel appraisal of the two subtypes, 
suggesting that while "typical"(or melancholic) depression has core 
pathophysiological features of overactive HPA-axis, what we call "atypical" 
depression may rather be comprehended as immuno-metabolic depression (Penninx 
et al., 2016). The precise interaction of potentially decreased activity of the HPA-axis 
with immune and metabolic abnormalities in the atypical subtype remains to be 
investigated. 
CONCLUSION
The correct definition of depression subtypes remains a cornerstone in biological 
research in affective disorders. The evaluation of study results is dramatically 
hampered by the variation of definitions, and there is very little consistency between 
research groups in what they name "endogenous" or "melancholic" depression. Our 
review confirmed the presence of different HPA axis function between Melancholic 
and Atypical Depression, and a trend towards a more robust association with 
biological, or vegetative symptoms, or reverse vegetative symptoms, respectively. 
Patients with Melancholic depression are associated with increased cortisol levels, 
both baseline and post different challenges. Moreover, the research data also 
suggest a reduction of inhibitory feedback in patients with melancholic depression, 
demonstrated by increased cortisol concentrations and the number of non-
suppressive patients following HPA axis challenge, mainly dexamethasone. Whether 
the difference between melancholic and atypical subtypes is better explained by the 
true hyperactive HPA-axis in the latter or a rather normal function. 
Future studies might need to focus on evaluating the symptom profiles in patients 
with definite HPA-axis abnormalities to identify symptom constellations that are 
strongly associated with neuroendocrine variations rather than rely on phenomeno-
logically defined subtypes. Moreover homogenize samples and methods, assessing 
more naturalistic measures, like salivary, hair or nails cortisol levels. Further insights 
into the dichotomy addressed in this review might be obtained from genetic and 
epigenetic studies of HPA-axis related genes in both subtypes, with an emphasis on 
the presence of vegetative symptoms. 
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Figure 1 Prisma Flow Diagram
    
 
 
 
     
 
TABLE 1: Melancholic depressed studies 
 
Type of 
meas-
urement 
Author, 
year 
Dose 
(For 
chal-
lenge 
tests) 
Measure-
ment time 
(s) 
Thres
hold 
(for 
chal-
lenge 
tests) 
Subtype 
definition 
№ of subjects Comparison group Results 
Dexa-
methaso
ne Sup-
pression 
Test 
(DST) 
Carroll et 
al., 1981a 
Dose 
1:1 mg 
(n=183) 
Dose 2: 
2 mg 
(n=185) 
8 am 
4 pm 
11 pm 
3, 4, 5, 
and 6 
µg/dL 
com-
pared 
Endogenous 
- RDC 
Endogenous 
- Clinical  
assessment 
(matching 
RDC in 98% 
cases)  
n = 47 non-endogenous: n = 42  
(of them n = 32  
neurotic depression)  
Sensitivity for   
melancholic 
depression:       
39% to 53% 
Specificity:      
85% to 97% 
Diagnostic        
confidence:  
83% to 93% 
Banki et 
al. 1986 
1 mg  8 am 
3 pm 
50 ng/dL DSM-III  
melancholic 
MDD  
n = 21  DSM-III melancholic MDD  
n = 15 healthy controls  
n = 20 schizophrenia  
n = 11 alcohol dependence  
n = 13 adjustment disorder 
67% NS in the 
Mel group vs 26% 
in the schizophre-
nia+adjustment 
disorder group 
    
 
 
 
     
Evans et 
al., 1986 
1 mg  4 pm  
11 pm 
5 µg/dl  DSM-III mel-
ancholic 
MDD  
n = 23 n = 23 non-melancholic 
MDD 
n = 19 psychotic MDD  
Highest rate of 
non-suppression in 
psychotic patients 
(95% vs 78% in 
MEL group at 5 
µg/dl, p<0.001); 
Higher non-
suppression rates 
in MEL depres-
sion vs non-MEL 
(48%, p<0.02)  
Miller et 
al., 1987 
1 mg 4 pm 
11 pm 
7 µg/dl DSM-III+ 
Endogenous - 
RDC  
Individual 
symptoms: 
Yale Depres-
sion Inventory  
n = 45 MDD + 
melancholia  
n = 39 MDD  
+ 5 psychotic MDD 
+ 3 bipolar depression 
+ 3 schizoaffective  
DST non-
suppression     
correlated with: 
both melancholic 
and endogenous 
subtype; 
insomnia; agita-
tion;  
loss of sexual    
interest; 
weight loss 
Rubin et 
al., 1987 
1 mg 7 am 
3 pm 
11 pm 
3,5 µg/dl  RDC «defi-
nite»  
endogenous  
n = 40  n = 40 healthy subjects  38% NS in the 
endogenous 
group vs 12% in 
controls 
    
 
 
 
     
Casper et 
al., 1987 
1 mg 8.30 am 
4 pm 
10 pm 
6 µg/dl Loss of appe-
tite: items 12 
on the Hamil-
ton scale (30), 
32 on Vibes 
(31), HSCL-
90, item 19 
(32), and 
SADS-C item 
228 (28).  
Weight loss: 
continuous 
severity 
measures 
from 1lb or 
more  
n = 38 
MDD patients 
with: weight 
loss and/or ap-
petite loss  
n = 42 
MDD patients without 
weight/appetite loss  
n = 80 control subjects  
Depression with 
weight/appetite 
loss associated 
with increased   
basal and post-
Dex cortisol at all 
time points com-
pared to MDD 
without 
weight/appetite 
loss  
    
 
 
 
     
Winokur 
et al., 1987 
1 mg 8 am 
and/or 4 
pm 
  
"Strong      
suppres-
sors":   
cortisol 
equal to 
or lower 
than 1.5 
µg/dl, n 
= 163      
High 
non-
suppres-
sors: 
(cortisol 
equal to 
or great-
er than 6 
µg/dl, 
n=164)  
DSM-III mel-
ancholic 
MDD  
n = 423 MDD 
patients  
no healthy controls  Melancholia      
significantly       
associated with 
high-degree       
non-suppression  
(24% vs 9%, 
p=0.01).  
  
    
 
 
 
     
Berger et 
al., 1984 
1,5 mg 
or 
1 mg 
 
4 pm 
11 pm 
5 mg/dl  
or  
8 mg/dl  
RDC/ICD/Ne
wcastle Scale  
SAMPLE 2: 
n = 45 MDD, of 
them 
n = 20 endoge-
nous  
SAMPLE 3: 
n = 93 psychiat-
ric patients, of 
them 
n = 41 endoge-
nous MDD, 
n = 52 other 
diagnoses  
SAMPLE 4: 
n = 93, of them 
n = 19 endoge-
nous MDD 
n = 74 patients 
with other diag-
noses  
SAMPLE 1: 
n = 75 healthy subjects, of 
them 
n = 24 DST 1 mg 
n = 51 DST 1,5 mg  
SAMPLE 5: 
n = 24 fasting patients  
Control subjects: 
12% NS at 5 mg/dl 
2,7% NS at 8 mg/dl  
SAMPLE 2: 
no significant dif-
ferences in sup-
pression rates, 
however, 
Higher NS rates 
among patients 
with weight loss 
(p< 0.001)  
SAMPLE 3: 
38,6% in ED vs 
7,4% in non-ED (5 
mg/dl) 
29,5% vs 8,7% 
(5 mg/dl)  
SAMPLE 4:  
Higher NS rates in 
neurotic depression 
vs ED at both 
thresholds  
    
 
 
 
     
Barocka 
et al., 
1987 
1 mg 7 am  
4 pm 
5 µg/dl  ICD-10 En-
dogenous 
depression  
n=26 n = 22 neurotic depres-
sion +adjustment disor-
der  
77% non-
suppression in 
endogenous 
group 
vs 23% in non-
endogenous  
Amster-
dam et al., 
1989  
1 mg 4 pm 5 µg/dl DSM-III  
melancholic 
MDD  
n = 51  n = 21 non-melancholic 
MDD 
n = 37 healthy controls  
Larger mean     
cortisol values for 
all response val-
ues in melanchol-
ic non-
suppressors vs all 
other groups and 
healthy      con-
trols 
    
 
 
 
     
Halbreich 
et al., 1989 
1 mg 4 pm 
11 pm 
not spec-
ified 
DSM-III 
PTSD RDC 
MDD-
endogenous 
depression 
n = 14 
PTSD+MDD-
ED  
n = 23 MDD-
ED  
n = 21 healthy controls  No difference be-
tween PTSD pa-
tients with comor-
bid ED and con-
trols; not a single 
case of non-
suppression in the 
PTSD-ED group. 
Lower basal corti-
sol and higher dex 
suppression rates 
in PTSD-ED vs 
MDD-ED   
Paslakis et 
al., 2009  
1,5 mg 2 pm 
3 pm 
non-
specified 
(assessed 
as a con-
tinuous 
measure) 
DSM-IV 
(SCID-IV)  
n = 26  n = 33 healthy controls  Higher post-Dex 
cortisol on MEL 
patients (28.24 
ng/ml vs 12.1 
ng/ml, p=0.02) 
    
 
 
 
     
Maes M. 
et al., 1989
  
 
 
 
  
 
 
  
 
  
1 mg 8 am Non-
specified  
(assessed 
as a con-
tinuous 
measure) 
Psychopatho-
logical corre-
lates:  
A. 14 SCID 
items  
B. Clustering:  
1.«biological» 
cluster: in-
crements in 
FT, residual 
cortisol, and 
ACTH, and 
by decrements 
in basal TSH, 
L- TRP, and 
L-TRP ratio 
(all p < 0.001)  
2.«non-
biological» 
cluster»  
C. Vital (6 
symptoms) vs 
Nonvital (7 
symptoms) 
syndrome as 
validated in 
previous stud-
ies by Maes et 
al., 1990 (Pt 
1) 
n = 96 
patients 
assessed for 
individual 
symp-
toms/presence 
of «vital» clus-
ter;  
n = 33 «vital»  
for the vital/nonvital distinc-
tion: 
n = 53 «nonvital»  
DST nonsupres-
sion significantly 
associated with 
symptoms of ano-
rexia, insomnia 
and early morning  
awakening;  
  
  
  
  
   
  
  
   
    
 
 
 
     
Peselow 
E.D. et al., 
1992  
1 mg 8-9 am +  
4-5 pm 
5 µg/dl  RDC definite 
endogenous 
subtype; DSM 
III melanchol-
ic subtype  
1) Meeting 
both RDC and 
DSM- III crite-
ria for melan-
cholia:  
n = 42  
2) Meeting ei-
ther RDC or 
DSM-III crite-
ria for melan-
cholia: n - 20  
MDD meeting neither RDC 
nor DSM-III criteria for en-
dogeneicity/melancholi a:  
n = 43 
Healthy subjects:  
n - 29  
Morning post-
DST plasma corti-
sol; Afternoon 
post-DST plasma 
cortisol and 
Frequency of ab-
normal DST sig-
nificantly elevated 
in «both» vs «nei-
ther» subtype and 
in «both» vs con-
trols  
Hubain et 
al., 1996  
1 mg 
  
4 pm 
11pm  
 50 ng/dl  Newcastle E   
ndogenous 
Depression 
Diagnostic 
Index 
(NEDDI):  
>= 6 for en-
dogenous <6 
for non- en-
dogenous  
n = 155 MDD 
endogenous  
n = 155 MDD non-
endogenous  
Cortisol post-DST 
significantly ele-
vated in ED only 
at 16.00 (p<0.01), 
but not at 23.00 
Controlled for age 
and severity, post-
DST 4 pm cortisol 
no longer signifi-
cantly associated 
with ED 
Valdivieso 
et al., 1996  
1 mg 8 am 
4 pm 
11 pm 
≥ 138 
nmol/l.l  
  
DSM-III mel-
ancholic de-
pression  
n = 18 melan-
cholic MDD  
n = 29 non-melancholic 
MDD  
n = 20 
healthy volunteers  
Higher levels of 
DST non- sup-
pression in the 
MEL group 
(p=0.004) 
    
 
 
 
     
Orsel, S. 
et al., 2010
  
 
 
 
  
 
 
  
 
  
1 mg 8 am 3.5 g/dl  DSM-III    
melancholic 
depression + 
cluster       
analysis 
which identi-
fied    «endo-
genous» and 
«non-
endogenous» 
subtype  
Discrimina-
tors: 
•early morn-
ing awaken-
ing  
• distinct 
quality of 
mood  
• feelings of 
guilt, non-
reactivity  
• suicidal 
ideation  
•psychomotor 
disorders  
n = 38     
(DSM-III      
criteria)  
n = 40          
«endogenous» 
cluster          
(included both 
DSM mel and 
non-mel       
patients)  
DSM-III criteria:  
n = 40 nonmelancholic MDD,  
incl.  
n = 27 «simple» MDD  
n = 4 BD1  
n = 2 Dysthymia  
n = 5 Depressive disorder NOS  
n = 2 Adjustment disorder  
«Non-endogenous» cluster:    
(included 8 mel patients) n = 38  
Only non-
reactivity dif-
fered signifi-
cantly between 
non-suppressors 
and suppressors 
(p<0.01)  
  
  
  
  
   
  
  
   
 
 
  
    
 
 
 
     
Other challenge tests 
d Fenflu-
ramine 
O’Keane, 
1991. 
30mg Baseline 
at 8:30; 
After 
challenge 
every 60 
minutes, 
for 5 
hours 
Quantita-
tive, 
compari-
son be-
tween 
groups 
DSM III        
criteria 
23 DMS III R 
criteria 
16 healthy control    
subjects 
High baseline cortisol 
levels were correlated 
with severity of               
depression (p<0,01) and 
weight loss (p<0,01). 
No difference between 
groups after challenge 
d Fenflu-
ramine 
Mitchell, 
1990 
60mg 8 am (3 
baseline 
measures 
20 min, 
apart); 
after that 
challenge 
and 5 
hourly 
measures 
Quantita-
tive, 
compari-
son be-
tween 
groups 
Varied         
according to 
used criteria: 
DSM III  
RDC ,  
ICD-9,  
Newcastle 
scale  
16 DSM III 
 
18 RDC  
 
15 ICD-9 
 
7 Newcastle 
scale  
14/ 12/ 15 /23 for each 
group 
No significant cortisol 
differences between 
groups 
    
 
 
 
     
ACTH Amster-
dam, 1989 
250ug 
(ACTH
) 
8:30 3 
baseline 
measures
; after 
ACTH 
30,60,90,
120,180,
240 min 
Quantita-
tive 
compari-
son 
HDRS 1st:  16 
(9 with       
melancholic 
features); 
 
2nd: 72  
(51 with     
melancholic 
features,        
21 without) 
1st: 11 healthy controls 
 
 
 
 
2nd: 37 healthy con-
trols 
1st: No difference be-
tween groups at base-
line. Larger increases in 
cortisol in the MDD 
group after ACTH 
(p<0,02); 
2nd: No difference at 
baseline; no statistically 
significant differences 
between groups, but a 
trend to higher cortisol 
levels in the melanchol-
ic group (P=0,31). 
    
 
 
 
     
oCRH  Amster-
dam, 1989 
1,0ug/k
g 
8:30. 3 
(every 15 
minutes) 
baseline 
measures 
for ACTH 
and corti-
sol lev-
els;  
after 
oCRH:0, 
30,60,90,
120,180, 
240 min 
 HDRS 26  
(14  
melancholic 
features) 
11 healthy controls No difference in cortisol 
levels after challenge; 
depressive patients had 
lower ACTH response 
compared to controls. 
(p<0,05)  
The effect was larger in 
melancholic features 
(p<0,04) 
Dex/CRH 
test 
Paslakis, 
2010 
100ug 
hCRH 
3 pm of 
day 2 (1 
day after 
DST) 
Quantita-
tive   
compari-
son 
HDRS 21 26 moderate to 
severe melan-
cholic depres-
sion 
33 healthy controls Low specificity and low 
sensibility for the 
CRH/Dex test (78.8% 
and 30,8% respectively) 
 
 
  
    
 
 
 
     
Basal Measures 
 
 
Type of  
measurement 
Authors, year Time/source of 
measurement 
Subtype definition Sample size Control group Results 
Basal cortisol 
levels 
Rubin et al., 
1987 
26-hour cortisol 
curve: 
Blood sampling eve-
ry 30 minutes over 26 
hours 
 
urinary free cortisol 
RDC «definite»  
endogenous  
n = 40 n = 40 healthy  
subjects 
DST NS vs  Supressors: 
-  elevated 24-hour     corti-
sol (11.4 vs 8.3 nmol/L, 
p<0.01)  
-  elevated nocturnal   nadir 
(3.1 vs 1.8 nmol/L, p< 
0.04) 
Only a moderate correla-
tion between basal serum 
and UFC cortisol 
    
 
 
 
     
Casper et al., 1987  Morning plasma cor-
tisol obtained at 8:30 
a.m. on days 9, 10, 
12.  
Evening plasma cor-
tisol level drawn at 
10 p.m. on Day 12. 
CSF cortisol sample - 
lumbar puncture at 9 
a.m. on Day 11. 
 A 24-hour urine pre-
dexamethasone 
collection assayed for 
urinary free cortisol 
(UFC) 
completed at 10:35 
p.m. on Day 12. 
Loss of appetite: items 12 
on the Hamilton scale 
(30), 32 on Vibes (31), 
HSCL-90, item 19 (32), 
and SADS-C item 228 
(28).  
 
Weight loss:            con-
tinuous severity measures 
from 1lb or more  
n = 38 
MDD patients with: 
weight loss and/or 
appetite loss  
n = 42 
MDD patients without 
weight/appetite loss  
n = 80 control subjects  
Basal plasma cortisol sig-
nificantly associated  with 
weight loss and appetite 
loss  
Guechot et al., 1987  baseline salivary cor-
tisol 
11 pm saliva cortisol 
DSM-III 
Saint-Louis criteria for 
primary endoge-
nous/seconda ry       de-
pression  
DSM-III 
Saint-Louis criteria 
for primary         en-
dogenous/seconda ry 
depression  
n = 40 «secondary 
depressive»  
n = 20 «non-
depressive»  
Higher saliva cortisol in 
endogenous depressives vs    
secondary  (p<0.05)/                    
non-depressives           (p< 
0.02)  
Amsterdam et al., 
1989  
basal morning plasma     
cortisol (8.30 am) 
DSM-III  
melancholic MDD  
n = 26  
(14 melancholic fea-
tures) 
n = 11 healthy con-
trols 
No difference in basal cor-
tisol concentration between 
melancholic and non-
melancholic groups 
    
 
 
 
     
Halbreich et al., 
1989  
basal plasma      cor-
tisol 
at 11 pm 
DSM-III PTSD RDC 
MDD-ED  
n = 14 PTSD+MDD-
ED  
n = 23 MDD-ED  
n = 21 healthy  
controls  
Lower basal cortisol in       
PTSD-ED vs MDD-ED  
Wong et al., 
2000  
basal plasma      cor-
tisol 
began 9.00-10.00 am 
every 30 min for 30 
hours 
DSM-III-R RDC  n = 10  n = 14 healthy    con-
trols  
Elevated basal   cortisol in 
MEL patients vs   controls 
(p<0.02) 
Michopoulos et 
al., 2008  
basal morning    cor-
tisol levels 
Salivary test to assess 
cortisol levels (three 
daily samples: morn-
ing, 08.00 a.m. 
[CS1]; noon, 16.00 
p.m. [CS2] and night, 
23.00 p.m) 
DSM-IV (SCID-IV)  n = 20  n = 20 non-mel 
n = 20 healthy    con-
trols  
No significant            ele-
vation in MEL group  
Paslakis et al., 
2009  
24-hour basal plasma 
cortisol 
DSM-IV (SCID-IV)  n = 26 n = 33 healthy   con-
trols  
Basal cortisol             sig-
nificantly elevated in MEL 
group  
Marquez-Deak 
et al., 2007  
Basal plasma cortisol 
8.00 am 
DSM-IV (SCID-IV)  n = 28 female    mel-
ancholic MDD  
n = 41 healthy    con-
trols  
n = 18                 non-
melancholic MDD  
No significant             dif-
ferences indicated between 
groups  
    
 
 
 
     
Mulder et al., 
2003  
Basal plasma cortisol 
at 09.00 h, blood 
drawn at 30-min in-
tervals over 3 h 30 
min 
DSM-III-R  n = 39  
melancholic MDD  
n = 69 non-
melancholic MDD, 
n = 20 control     sub-
jects  
No significant             dif-
ferences                  indicat-
ed between groups  
Joyce, P.R. et al., 
2001  
Basal plasma cortisol  
(13.00 - 15.00 at 15-
min intervals) 
DSM-IV melancholic 
MDD  
 
vs 
 
CORE checklist 
n = 86 melancholic 
patients  
n = 32 «severely mel-
ancholic»      patients  
CORE definition: 116 
«broadly      defined»            
melancholic         pa-
tients;  
39 «narrowly       de-
fined»             melan-
cholic patients  
n = 77  
non-melancholic pa-
tients  
No differences on any pa-
rameters between DSM-
IV-defined groups  
CORE definition: 
Basal cortisol increased 
only in male patients in 
combined broad+narrow 
melancholic vs non-
melancholic groups 
(p = 0.016)  
O’Keane & Di-
nan, 1991 
Basal plasma      cor-
tisol 
Single measure at 
8.30 before         d,l-
fenfluramine test   
DSM-III-R, 
Newcastle scale 
n = 23 n = 16 healthy        
subjects 
Elevated in endogenous 
patients vs controls     (t= 
3,56; df=37, p=0.0001) 
High baseline cortisol cor-
related with HAM-D sever-
ity (r=0.97, p<0.001) and 
weight loss (r=0.85, 
p<0.001). 
    
 
 
 
     
Mitchell P. et al., 
1990  
Baseline plasma cor-
tisol  
Four different definitions 
of endogenicity/melanch 
oly compared:  
• ICD-9 
• DSM-III 
• RDC 
• Newcastle scale  
n = 15 (ICD-9) 
n = 16 (DSM-III) 
n = 18 (RDC) 
n = 7 (Newcastle sca-
le)  
n = 15 non-
endogenous (ICD-9) 
n = 14 non-
endogenous   (DSM-
III)  
n = 12 non-
endogenous (RDC) 
n = 23 non-
endogenous    (New-
castle scale)  
No significant             dif-
ferences in baseline corti-
sol in any           classifica-
tion  
Valdivieso et al., 
1996  
Baseline plasma cor-
tisol at midnight 
DSM-III melancholic 
depression  
n = 18 melancholic 
MDD  
n = 29 non-
melancholic MDD  
n = 20 
healthy volunteers  
No differences between 
depressed patients and con-
trols  
    
 
 
 
     
Orsel, S. et al., 
2010  
Basal plasma cortisol 
8 am 
 
DSM-III melancholic 
depression+cluster analy-
sis which        identi-
fied«endogenous» and 
«non-endogenous»   sub-
type  
Discriminators:  
• early morning    awak-
ening  
• distinct quality of mood  
• feelings of guilt, non-
reactivity  
• suicidal ideation  
• psychomotor disorders  
 
n = 38 (DSM-III crite-
ria)  
n = 40 «endogenous» 
cluster (included both 
DSM mel and non-
mel patients)  
DSM-III criteria:  
n = 40 nonmelanchol-
ic MDD, incl. 
n = 27 «simple» MDD  
n = 4 BD1  
n = 2 Dysthymia  
n = 5 Depressive dis-
order NOS  
n = 2 Adjustment dis-
order  
«Non-endogenous» 
cluster: (included 8 
mel patients) n = 38  
Significantly elevated basal 
cortisol in the   «ëndoge-
nous» cluster 
Liu et al., 2016  cortisol as part of 228 
metabolites 
The CORE scale for mel-
ancholic             depres-
sion;  
Anxious depression de-
fined as  
number of comorbid anx-
iety disorders on the 
M.I.N.I. International 
Neuropsychiatric     Inter-
view > 0  
n = 21 n = 58 anxious   de-
pression 
n = 100 healthy  con-
trols  
Increased basal cortisol in 
melancholia vs healthy 
controls;  
    
 
 
 
     
Basal ACTH 
measures 
Wong et al.  24-hour basal plasma 
ACTH 
began 9.00-10.00 am 
every 30 min for 30 
hours 
DSM-III-R, 
RDC (not specified which 
used for diagnosis of mel-
ancholia) 
n = 10 n = 14 healthy con-
trols 
No difference in plasma 
ACTH  
between patients and con-
trols 
 Joyce, P.R. et al., 
2001  
basal afternoon plas-
ma ACTH 
(13.00 - 15.00 at 15-
min intervals) 
DSM-IV melancholic 
MDD  
 
vs 
 
CORE checklist 
n = 86 melancholic 
patients  
n = 32 «severely mel-
ancholic»      patients  
CORE definition: 116 
«broadly      defined»            
melancholic         pa-
tients;  
39 «narrowly       de-
fined»             melan-
cholic patients 
n = 77  
non-melancholic pa-
tients  
No differences between 
groups independent of sub-
type 
    
 
 
 
     
 Gomez-Gil et al. basal morning plasma 
ACTH 
Newcastle Endogenous 
Depression Diagnostic 
Index (NEDDI):  
>= 7 for endogenous  
n = 14  n = 15  No difference in baseline 
ACTH between groups 
CRF Wong et al., 
2000  
Basal CSF CRF -  
CSF sampling began 
at 09:00–10:00 a.m. 
and lasted for 30 
hours 
DSM-III-R, 
RDC (not specified which 
used for diagnosis of mel-
ancholia) 
n = 10 n = 14 healthy con-
trols 
No difference in baseline 
CRF between groups 
    
 
 
 
     
 Joyce et al., 2001 Basal afternoon 
plasma CRF 
(13.00 - 15.00 at 15-
min intervals) 
DSM-IV melancholic 
MDD  
 
vs 
 
CORE checklist 
n = 86 melancholic 
patients  
n = 32 «severely mel-
ancholic»      patients  
CORE definition: 116 
«broadly      defined»            
melancholic         pa-
tients;  
39 «narrowly       de-
fined»             melan-
cholic patients 
n = 77  
non-melancholic pa-
tients  
No differences in basal 
plasma CRF between 
groups independent of sub-
type 
 
  
    
 
 
 
     
Table 2 Atypical vs. non-atypical or controls  
Type of 
measure-
ment 
Author, 
year 
Dose (For 
challenge 
tests) 
Measure-
ment time(s) 
Threshold 
(for chal-
lenge tests) 
Subtype definition № of subjects Comparison group Results 
Dexame-
thasone  
suppres-
sion 
test  
(DST) 
Casper et 
al., 1988 
1 mg 8.30 am 
4 pm 
10 pm 
5 µg/dl Hypersomnia/Increased 
appetite diagnosed with 
SADS 
Sample 1: n = 23 
MDD +  
hypersomnia 
Sample 2: n = 22 
MDD + 
incr.appetite 
 
n = 23 depressed  
patients without 
appetite/weight 
increase or 
hypersomnia 
 
n = 22 healthy  
subjects 
In patients with hyper-
somnia only: 
Significantly higher levels 
of morning suppression vs 
non-atypical depressed pa-
tients  
(P < 0.04). 
No difference between hy-
persomnia patients and con-
trols.  
In patients with weight 
gain only: 
no significant difference 
between patients and con-
trols 
In patients with both ap-
petite/weight gain and hy-
persomnia 
DST non-suppression simi-
lar to controls 
    
 
 
 
     
Thase et 
al., 1989  
1 mg 4 pm 5 µg/dl Own operational crite-
ria of anergia:  
1)  definite anergia  
(score 2 on HADRS-
13)  
2) psychomotor retar-
dation  
(score 2 or more on  
HADRS-13)  
3)  at least one of two  
associated reversed 
neurovegetative fea-
tures (weight gain 2.2 
kg or more, hyper-
somnia as +1 hour of 
extra sleep)  
n = 23 
«anergic bipolar»  
patients  
n = 26 healthy 
subjects  
13% DST nonsuppression 
rate (3/26 patients)  
Levitan 
et al., 
2002 
0.25/0.5 
mg 
8 am  
3 am 
percent 
change 
scores 
DSM-IV atypical de-
pression  
n = 8 female  
patients 
n = 11 healthy 
subjects  
91,9% suppression in atypi-
cal depressive patients vs 
78,3% in controls;  
Stewart 
et al., 
2005 
1 mg 4 pm 5 µg/dl DSM-IV atypical de-
pression  
n = 84 chronic 
atypical patients,  
of them 
31 early-onset, 53 
late-onset;  
61 chronic  
(disthymia)  
no healthy con-
trols (comparison 
between atypical 
groups) 
Lower mean. post- dexame-
thasone cortisol levels in 
early/chronic atypical vs 
late/nonchronic atypical 
patients  
    
 
 
 
     
Desipra-
mine chal-
lenge test 
Asnis et 
al., 1992 
75 mg 9 am: 
cortisol levels 
every 15 min 
for 1 hour;  
Imipramine vs 
placebo: 
blood test for 
2 hours, (eve-
ry 15 min for  
cortisol le-
vels; every 30 
min for desi-
pramine le-
vels) 
N/A 
(measured 
as a  
contiuous 
variable) 
 
 
ADDS  n = 33  n = 81 non-
atypical MDD  
 
Significantly higher post-
desipramine cortisol 
(blunted response)  
in atypical group 
vs non-atypical  
 
 
McGinn 
et al., 
1995  
75 mg 9 am: 
cortisol levels 
every 15 min 
for 1 hour;  
Imipramine vs 
placebo: 
blood test for 
2 hours, (eve-
ry 15 minutes 
for cortisol 
levels; every 
30 min for 
desipramine 
levels) 
N/A 
(measured 
as a conti-
uous varia-
ble) 
 
ADDS n = 17 atypical 
depressives (AD)  n = 19 mood re-
activity (MR) 
depressives, 
n = 36 non-
MR/AD MDD  
Significantly blunted  
response to DMI in AD 
compared to MR and  
controls  
 
    
 
 
 
     
Dextroam
-
phetamine 
stimulatio
n 
test 
Stewart 
et al., 
2005 
0.15 
mg/kg  
Cortisol levesl 
taken each 30 
min, from 
1pm to 4pm; 
After that 
Dextro stimu-
lation over 45  
seconds, and 
blood collect-
ed every 15 
min for 90min 
After 30 
minutes of 
Dextro  
infusion, 
cortisol 
levels 
<1,5µg/dL 
were con-
sidered  
abnormal 
DSM-IV n = 84 no HC group No significant differences 
between groups  
(early/chronic atypical vs 
late/nonchronic atypical) 
oCRH 
stimula-
tion test 
Joseph-
Vander-
pool, J.R. 
et al., 
1991  
100 ng  Cortisol levels 
taken 15 
minutes be-
fore challenge 
(9am); then at 
the time, 5, 
10, 15, 30, 60, 
90 and 120 
minutes later 
Quantita-
tive  
between 
groups 
DSM-III-R  
 
SAD with reverse 
vegetative symptoms/ 
Major depression 
with seasonal pattern  
n = 10 SAD pa-
tients  
 
 
 
 
 
n = 13 healthy 
controls  
ACTH and cortisol  
responses to oCRH  
significantly blunted in 
untreated SAD  
vs controls; 
Delayed timing of the 
ACTH peak vs controls 
 
 
 
 
 
    
 
 
 
     
 
 
Table 2 Atypical vs non-atypical or controls. Basal cortisol and ACTH levels 
Type of 
measure-
ment 
Authors, 
year 
Time/source 
of 
measure-
ment 
Subtype  
definition 
Sample  
size 
Control  
group 
Results 
Basal corti-
sol 
Levitan at 
al., 1997  
baseline  
plasma corti-
sol 
at 8am 
DSM-III for  
Bulimia Nervosa  
HDRS-29 to  
assess reversed 
neurovegetative 
symptoms 
n = 16 
«bulimia  
nervosa»  
with atypi-
cal features  
n = 14 healthy controls  Strong negative correlation for hypersomnia 
and basal cortisol levels; 
for «carbohydrate craving» and basal cortisol 
levels  
 Anisman et 
al., 1999  
baseline 
plasma corti-
sol at 7am, 
and each 10 
minutes until 
9:30am 
ADDS  
DSM-III/IV,  
HAM-D-29  
n = 31  
atypical  
depressed 
patients,  
n = 15  
atypical  
dysthymic 
patients,  
n = 14 non-atypical 
depressed patients;  
n = 14 non-atypical  
dysthymic patients 
Decreased basal cortisol in atypical de-
pressed subjects vs controls  
    
 
 
 
     
 Casper et 
al., 1988 
Basal plasma 
cortisol 8 am 
on days 
9,10,12 (fur-
ther  
averaged) 
Basal CSF 
cortisol: 8-
8.30 am 
Basal urinary 
cortisol: 
24-h specimen 
Hypersomnia/ 
Increased appe-
tite diagnosed 
with SADS 
Sample 1:  
n = 23  
MDD + 
hyper-
somnia 
Sample 2:  
n = 22  
MDD + 
incr.appetite 
 
n = 23 depressed pa-
tients without appe-
tite/weight increase or 
hypersomnia 
n = 22 healthy subjects  
1.Morning plasma cortisol higher in MDD 
without H or AI vs controls, no difference oth-
erwise  
2.Urinary free cortisol: higher in all MDD 
groups vs controls  
3.No significant differences in CSF cortisol  
 
 Levitan et 
al., 2002 
basal plasma 
cortisol 
(11 pm) 
DSM-IV atypi-
cal depression 
n = 8 n = 11 Lower basal cortisol in subjects vs controls 
 Stewart et 
al., 2005 
basal plasma 
cortisol 
3-hour after-
noon cortisol 
curve 
DSM-IV atypi-
cal depression 
n = 84 no HC group Lower mean 3 h afternoon cortisol levels 
(N=21) in early/chronic atypical vs 
late/nonchronic atypical patients  
 Asnis et al., 
1992 
basal 
morning  
plasma corti-
sol 
ADDS n=33 n=81 No difference between atypical and non-
atypical depression (reported as “no effect 
for group on baseline cortisol levels”) 
    
 
 
 
     
 McGinn et 
al., 1995 
basal  
morning  
plasma corti-
sol 
ADDS n = 17 n = 19 MR patients 
n = 19 non-MR/AD-
MDD patients 
No difference in baseline cortisol between 
any groups  
 Joseph-
Vander-
pool, J.R. 
et al., 1991  
basal plasma 
cortisol 
(24-hour 
curve) 
DSM-III-R n = 10 n =13 Basal cortisol levels NS lower in patients 
vs controls except 
at 22.00 when basal cortisol in patients was 
significantly lower vs controls 
(46.59 ± 27.59 nmol/L vs. 137.95 ± 71.73 
nmol/L; p= 0.02)  
Basal ACTH Anisman et 
al., 1999 
Basal ACTH 
at 7am, and 
each 10 
minutes until 
9:30am 
ADDS  
DSM-III/IV, 
HAM-D-29  
n = 31 
MDD 
n = 15  
dysthymia 
n = 14 non-atyp 
MDD;  
n = 14 non-atyp  
dysthymia  
Increased basal ACTH in atypical de-
pressed subjects vs controls  
 
 
 
  
    
 
 
 
     
TABLE 3 ATYPICAL DEPRESSION VS. MELANCHOLIC DEPRESSION. BASAL CORTISOL. BASAL ACTH, DST, DEX/CRH 
Type  
of 
measurement 
Authors, 
year Measurement time 
Definition of 
melancholic 
subtype/ sample 
size 
Definition of 
atypical subtype/ 
sample size 
Comparison group Results 
Basal 
cortisol 
Young et 
al., 2001  
24-hour plasma cor-
tisol: 9 am-9 am; 
10-min intervals 
24-hour urinary cor-
tisol  
RDC definite 
endogenous; 
n=6 
DSM-IV criteria;  
n=7 
n = 25 neither sub-
type MDD  
A trend towards elevated 
cortisol in definite 
endogenous patients; 
normal cortisol in 
atypical patients. No 
significant differences. 
Brouwer et 
al., 2005  
Morning basal se-
rum cortisol 
 (before 10am)  
24-h urinary cortisol  
DSM-IV  
n = 32 
DSM-IV  
n = 25 
n = 56 MDD neither 
subtype  
n = 113 control sub-
jects  
Serum cortisol lower in 
AD vs neither subtype 
MDD only  
Karlovic et 
al., 2012 
Baseline morning 
serum cortisol be-
tween 8am and 9am 
DSM-IV  
n = 32 
DSM-IV  
n = 23 
n = 18  Serum cortisol signifi-
cantly 
higher in MDD-M vs 
MDD-A, and in MD vs 
control  
Similar in AD and con-
trols.  
    
 
 
 
     
Type  
of 
measurement 
Authors, 
year Measurement time 
Definition of 
melancholic 
subtype/ sample 
size 
Definition of 
atypical subtype/ 
sample size 
Comparison group Results 
 Lamers et 
al., 2012  
Saliva cortisol 
awakening curves 
(CAR 30, 45 and 60 
minutes later. Addi-
tional sample at 
11am. Diurnal corti-
sol slope  
CIDI + previous la-
tent class analysis 
(own operational 
criteria) of patients 
with persistent 
chronic depression  
n = 122 
CIDI + previous 
latent class analy-
sis (own opera-
tional criteria) 
of patients with 
persistent chronic 
depression  
n = 111 
n = 543 healthy 
controls  
Lower AUCg, lower di-
urnal cortisol slope in 
atypical vs melancholic 
patients and vs controls  
Cizza et al., 
2012  
24-hour serum cor-
tisol, hourly, start-
ing at 8am. 
DSM-IV  
n = 53 
DSM-IV  
n = 16 
n = 22 neither sub-
type MDD  
n = 44 healthy con-
trols  
No variation in serum 
cortisol levels  
Basal 
ACTH 
Young et 
al., 2001  
24-hour plasma 
ACTH   
9 am-9 am; 
10-min intervals 
RDC 
n = 6 
DSM-IV 
n = 7 
n = 25 neither sub-
type MDD  
No difference between 
groups; 
a trend toward increased 
ACTH in endogenous 
patients vs controls. 
    
 
 
 
     
Type  
of 
measurement 
Authors, 
year Measurement time 
Definition of 
melancholic 
subtype/ sample 
size 
Definition of 
atypical subtype/ 
sample size 
Comparison group Results 
Cizza et al., 
2012  
24-hour serum cor-
tisol hourly, starting 
at 8am.  
DSM-IV  
n = 53 
DSM-IV  
n = 16 
n = 22 neither sub-
type MDD  
n = 44 healthy con-
trols  
Significant increase in 
serum ACTH in atypical 
group vs controls  
 
DST 
Fountolakis 
et al., 2004 
 
1 mg 4 pm 
11 pm 
5 µg/dl  DSM-IV/ICD-10  
n = 16  
DSM-IV/ICD-10  
n = 14  
DST/CRH Heinzmann 
et al., 2014 
Dex: 0.05 mg/kg - 2 
mg/kg CRH dose: 
0.15 mg/kg. 
11.30 pm AUC measurement Based on AUC 
response to 
Dex/CRH, 
patients (n=657) 
were divided into: 
 
hHR: 219  
hLR:219 
hIR: 219  
n/a 
 
 
    
 
 
 
     
 
TABLE 4 LONGITUDINAL STUDIES 
 
Authors, 
year 
Type of 
measurement 
(incl.dose 
and timing 
specifications) 
Design 
Sub-
type 
+ 
sample 
size 
Subtype  
definition 
Comparison  
group Results 
Haskett et 
al., 1987 
Dexamethasone 
Suppression Test  
(1 mg;  
4 pm-11 pm,  
5 ng/dL) 
DST  
performed on  
admission  
(day 1-2) and 
after  
7-12 days 
Endo-
genous 
Depres-
sion 
RDC "definite  
endogenous"  
depression 
Non-
endogenous 
MDD patients, 
incl."probable 
endogenous" 
Non-suppression rates significantly 
lower at second DST overall and in 
nonpendogenous patients, 
Non-suppression rates did not signi-
ficantly decrease in the ED group 
Geracioti et 
al., 1992 
Basal plasma cor-
tisol 
 (biweekly tests at 
7.30 am) 
6-month follow-
up 
Atypical 
Depres-
sion 
Clinical  
assessment  
(the presence of 
reversed neu-
rovegetative 
signs) 
n/a Eucortisolemic in acute depression 
(on admission) 
Negative correlation between mood 
ratings and serum cortisol (r = - 0.36, 
p = 0.002)  
Steiger et 
al., 1997 
Basal plasma cor-
tisol  
(from 23.00  
until 07.00) 
Time 1. On 
admission 
Time 2. Post-
treatment 
Endo-
genous 
Depres-
sion 
RDC n = 25 normal 
controls  
      
Basal cortisol significantly elevated in 
ED vs controls;  
in ED on admission vs ED post-
treatment 
    
 
 
 
     
Pintor et al. 
2013 
Plasma ACTH 
levels following 
100 µg hCRF 
stimulation test  
Plasma cortisol 
levels follow-
ing100 µg hCRF 
stimulation test  
Patients fol-
lowed-up for 2 
years after 
hCRF stimula-
tion  
 
NAUCC 
stratified at 
three 
levels —  
<150;  
150 – 350 and 
  >350  
µg/ml/min 
melan-
cholic 
patients 
n = 62  
  
DSM-IV melan-
cholic MDD, 
confirmed by 
MES, NEDDI  
n = 23 healthy 
subjects  
No differences between relapsed, 
non-relapsed or partially relapsed 
groups; 
Significant differences between pa-
tient groups and controls on both 
ACTH and cortisol  
significant difference only between 
complete relapse groups and controls  
Kaestner et 
al., 2005 
• Basal plasma 
ACTH (8 am) 
• Basal plasma 
cortisol (8 am) 
Time 1. On 
admission 
Time 2. Post-
treatment 
Endoge-
nous  
Depres-
sion 
n = 21 
DSM-IV + 
Newcastle  
Endogenicity 
Scale 
6 points or more  
n = 16 non-
melancholic  
patients 
n = 37 healthy 
controls   
Plasma ACTH increased in both 
acute and remitted MEL patients vs 
controls.  
Elevated plasma cortisol in acute 
melancholic vs control groups only  
Non-MEL patients not different from 
control on either measure  
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